WO2017025944A2 - Macrophage car (moto-car) in imunotherapy - Google Patents
Macrophage car (moto-car) in imunotherapy Download PDFInfo
- Publication number
- WO2017025944A2 WO2017025944A2 PCT/IB2016/056140 IB2016056140W WO2017025944A2 WO 2017025944 A2 WO2017025944 A2 WO 2017025944A2 IB 2016056140 W IB2016056140 W IB 2016056140W WO 2017025944 A2 WO2017025944 A2 WO 2017025944A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tumor
- macrophage
- macrophages
- cells
- cancer
- Prior art date
Links
- 210000002540 macrophage Anatomy 0.000 title claims abstract description 254
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 261
- 201000011510 cancer Diseases 0.000 claims abstract description 121
- 210000002865 immune cell Anatomy 0.000 claims abstract description 20
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 210000004027 cell Anatomy 0.000 claims description 101
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 60
- 239000000427 antigen Substances 0.000 claims description 56
- 102000036639 antigens Human genes 0.000 claims description 55
- 108091007433 antigens Proteins 0.000 claims description 55
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 41
- 230000004913 activation Effects 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 33
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 claims description 31
- 210000001616 monocyte Anatomy 0.000 claims description 25
- 210000004881 tumor cell Anatomy 0.000 claims description 25
- 102000002689 Toll-like receptor Human genes 0.000 claims description 23
- 108020000411 Toll-like receptor Proteins 0.000 claims description 23
- 230000011664 signaling Effects 0.000 claims description 21
- 238000002560 therapeutic procedure Methods 0.000 claims description 16
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 14
- 102000005962 receptors Human genes 0.000 claims description 13
- 108020003175 receptors Proteins 0.000 claims description 13
- 230000001086 cytosolic effect Effects 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 108010036901 thymidine kinase 1 Proteins 0.000 claims description 9
- 239000013598 vector Substances 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 230000003834 intracellular effect Effects 0.000 claims description 8
- 210000004698 lymphocyte Anatomy 0.000 claims description 6
- 210000004443 dendritic cell Anatomy 0.000 claims description 5
- 230000004927 fusion Effects 0.000 claims description 5
- 230000002147 killing effect Effects 0.000 claims description 5
- 210000000265 leukocyte Anatomy 0.000 claims description 5
- 101100231743 Homo sapiens HPRT1 gene Proteins 0.000 claims description 3
- 108091006088 activator proteins Proteins 0.000 claims description 2
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 claims 6
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 84
- 108020004440 Thymidine kinase Proteins 0.000 description 84
- 230000010287 polarization Effects 0.000 description 54
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 42
- 238000011160 research Methods 0.000 description 32
- 102000004127 Cytokines Human genes 0.000 description 31
- 108090000695 Cytokines Proteins 0.000 description 31
- 108090000623 proteins and genes Proteins 0.000 description 31
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 27
- 230000037361 pathway Effects 0.000 description 23
- 210000003690 classically activated macrophage Anatomy 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 22
- 238000009169 immunotherapy Methods 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 21
- 230000004614 tumor growth Effects 0.000 description 21
- 102000004190 Enzymes Human genes 0.000 description 20
- 108090000790 Enzymes Proteins 0.000 description 20
- 230000006870 function Effects 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 230000004083 survival effect Effects 0.000 description 19
- 230000033115 angiogenesis Effects 0.000 description 16
- 238000001727 in vivo Methods 0.000 description 16
- 210000004322 M2 macrophage Anatomy 0.000 description 15
- 238000005516 engineering process Methods 0.000 description 15
- 208000026310 Breast neoplasm Diseases 0.000 description 14
- 206010027476 Metastases Diseases 0.000 description 14
- 230000009401 metastasis Effects 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 229940122361 Bisphosphonate Drugs 0.000 description 13
- 108010065805 Interleukin-12 Proteins 0.000 description 13
- 102000013462 Interleukin-12 Human genes 0.000 description 13
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 13
- 102100040247 Tumor necrosis factor Human genes 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 230000008685 targeting Effects 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 206010006187 Breast cancer Diseases 0.000 description 12
- 150000004663 bisphosphonates Chemical class 0.000 description 12
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 12
- 230000002757 inflammatory effect Effects 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 11
- 108010050904 Interferons Proteins 0.000 description 11
- 102000004388 Interleukin-4 Human genes 0.000 description 11
- 108090000978 Interleukin-4 Proteins 0.000 description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
- 230000002491 angiogenic effect Effects 0.000 description 11
- 239000002158 endotoxin Substances 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- 229940028885 interleukin-4 Drugs 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 102000014150 Interferons Human genes 0.000 description 10
- 108010057466 NF-kappa B Proteins 0.000 description 10
- 102000003945 NF-kappa B Human genes 0.000 description 10
- 108091008874 T cell receptors Proteins 0.000 description 10
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 230000000770 proinflammatory effect Effects 0.000 description 10
- 108010074328 Interferon-gamma Proteins 0.000 description 9
- 102000003814 Interleukin-10 Human genes 0.000 description 9
- 108090000174 Interleukin-10 Proteins 0.000 description 9
- 239000012620 biological material Substances 0.000 description 9
- 238000002619 cancer immunotherapy Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 210000000987 immune system Anatomy 0.000 description 9
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- 102100037850 Interferon gamma Human genes 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 101710094705 Sedoheptulokinase Proteins 0.000 description 8
- 102100029990 Sedoheptulokinase Human genes 0.000 description 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 230000004153 glucose metabolism Effects 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 229940079322 interferon Drugs 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- 239000002679 microRNA Substances 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 7
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 7
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 108091070501 miRNA Proteins 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- PQGCEDQWHSBAJP-TXICZTDVSA-N 5-O-phosphono-alpha-D-ribofuranosyl diphosphate Chemical compound O[C@H]1[C@@H](O)[C@@H](O[P@](O)(=O)OP(O)(O)=O)O[C@@H]1COP(O)(O)=O PQGCEDQWHSBAJP-TXICZTDVSA-N 0.000 description 6
- 102000019034 Chemokines Human genes 0.000 description 6
- 108010012236 Chemokines Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 206010061309 Neoplasm progression Diseases 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 101800000628 PDH precursor-related peptide Proteins 0.000 description 6
- 230000018199 S phase Effects 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 230000022131 cell cycle Effects 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 239000000539 dimer Substances 0.000 description 6
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000011835 investigation Methods 0.000 description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 150000003212 purines Chemical class 0.000 description 6
- 230000007115 recruitment Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 102000011690 Adiponectin Human genes 0.000 description 5
- 108010076365 Adiponectin Proteins 0.000 description 5
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 5
- -1 CCL3 Proteins 0.000 description 5
- 108090000467 Interferon-beta Proteins 0.000 description 5
- 102000003777 Interleukin-1 beta Human genes 0.000 description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 description 5
- 101100165729 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) stk-1 gene Proteins 0.000 description 5
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 5
- 102000006381 STAT1 Transcription Factor Human genes 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 229920006317 cationic polymer Polymers 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 230000037353 metabolic pathway Effects 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 238000004064 recycling Methods 0.000 description 5
- 230000000241 respiratory effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 230000005747 tumor angiogenesis Effects 0.000 description 5
- 230000005751 tumor progression Effects 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 206010050685 Cytokine storm Diseases 0.000 description 4
- 230000005778 DNA damage Effects 0.000 description 4
- 231100000277 DNA damage Toxicity 0.000 description 4
- 230000010190 G1 phase Effects 0.000 description 4
- 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 4
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 4
- YFGBQHOOROIVKG-FKBYEOEOSA-N Met-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-FKBYEOEOSA-N 0.000 description 4
- 108010042237 Methionine Enkephalin Proteins 0.000 description 4
- 108700011259 MicroRNAs Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 4
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 4
- 102000014736 Notch Human genes 0.000 description 4
- 108010070047 Notch Receptors Proteins 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- 108010045717 Proto-Oncogene Proteins c-akt Proteins 0.000 description 4
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 102100034838 Thymidine kinase, cytosolic Human genes 0.000 description 4
- 230000035508 accumulation Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000005975 antitumor immune response Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 206010052015 cytokine release syndrome Diseases 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 4
- 210000000066 myeloid cell Anatomy 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 230000036284 oxygen consumption Effects 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000017423 tissue regeneration Effects 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 102000006306 Antigen Receptors Human genes 0.000 description 3
- 108010083359 Antigen Receptors Proteins 0.000 description 3
- 102100021723 Arginase-1 Human genes 0.000 description 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 3
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 3
- 108091011896 CSF1 Proteins 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 3
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 229930010555 Inosine Natural products 0.000 description 3
- 102100026720 Interferon beta Human genes 0.000 description 3
- 102100033446 Lymphocyte antigen 96 Human genes 0.000 description 3
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 3
- 102000013968 STAT6 Transcription Factor Human genes 0.000 description 3
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 101150045355 akt1 gene Proteins 0.000 description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 230000006023 anti-tumor response Effects 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 230000019522 cellular metabolic process Effects 0.000 description 3
- 229940124446 critical care medicine Drugs 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000034659 glycolysis Effects 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 230000002055 immunohistochemical effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000005007 innate immune system Anatomy 0.000 description 3
- 229960003786 inosine Drugs 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 230000009456 molecular mechanism Effects 0.000 description 3
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000010837 poor prognosis Methods 0.000 description 3
- 230000036515 potency Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- CEGXZKXILQSJHO-KODRXGBYSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanoyl fluoride Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC(F)=O CEGXZKXILQSJHO-KODRXGBYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- PRRZDZJYSJLDBS-UHFFFAOYSA-N 3-bromo-2-oxopropanoic acid Chemical compound OC(=O)C(=O)CBr PRRZDZJYSJLDBS-UHFFFAOYSA-N 0.000 description 2
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 2
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 2
- 101710129000 Arginase-1 Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 102000030431 Asparaginyl endopeptidase Human genes 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 201000007336 Cryptococcosis Diseases 0.000 description 2
- HAIWUXASLYEWLM-UHFFFAOYSA-N D-manno-Heptulose Natural products OCC1OC(O)(CO)C(O)C(O)C1O HAIWUXASLYEWLM-UHFFFAOYSA-N 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 208000007990 Giant Cell Tumor of Tendon Sheath Diseases 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 2
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 2
- 206010066476 Haematological malignancy Diseases 0.000 description 2
- 229940119173 Hexokinase 2 inhibitor Drugs 0.000 description 2
- 102100029242 Hexokinase-2 Human genes 0.000 description 2
- 101710198385 Hexokinase-2 Proteins 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 2
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 2
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 2
- 108010032038 Interferon Regulatory Factor-3 Proteins 0.000 description 2
- 102000002227 Interferon Type I Human genes 0.000 description 2
- 108010014726 Interferon Type I Proteins 0.000 description 2
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- HSNZZMHEPUFJNZ-UHFFFAOYSA-N L-galacto-2-Heptulose Natural products OCC(O)C(O)C(O)C(O)C(=O)CO HSNZZMHEPUFJNZ-UHFFFAOYSA-N 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 108091007772 MIRLET7C Proteins 0.000 description 2
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 2
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 206010067565 Pneumonia cryptococcal Diseases 0.000 description 2
- HAIWUXASLYEWLM-AZEWMMITSA-N Sedoheptulose Natural products OC[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@](O)(CO)O1 HAIWUXASLYEWLM-AZEWMMITSA-N 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 description 2
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 description 2
- 108700012411 TNFSF10 Proteins 0.000 description 2
- 201000008754 Tenosynovial giant cell tumor Diseases 0.000 description 2
- 241000949477 Toona ciliata Species 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- DILVWDXOASDRPN-MROZADKFSA-N [(2r,3r,4r)-3,4,5-trihydroxy-1-oxopentan-2-yl] dihydrogen phosphate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](C=O)OP(O)(O)=O DILVWDXOASDRPN-MROZADKFSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000006536 aerobic glycolysis Effects 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000011122 anti-angiogenic therapy Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 108010055066 asparaginylendopeptidase Proteins 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008238 biochemical pathway Effects 0.000 description 2
- 229960003008 blinatumomab Drugs 0.000 description 2
- 208000030270 breast disease Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000006369 cell cycle progression Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 230000007248 cellular mechanism Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002281 colonystimulating effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000003831 deregulation Effects 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 201000003914 endometrial carcinoma Diseases 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000000446 fuel Substances 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000004547 gene signature Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 229960001388 interferon-beta Drugs 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 238000011694 lewis rat Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000006680 metabolic alteration Effects 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000004145 nucleotide salvage Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000004108 pentose phosphate pathway Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000006825 purine synthesis Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000006884 regulation of angiogenesis Effects 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 108010078070 scavenger receptors Proteins 0.000 description 2
- 102000014452 scavenger receptors Human genes 0.000 description 2
- HSNZZMHEPUFJNZ-SHUUEZRQSA-N sedoheptulose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO HSNZZMHEPUFJNZ-SHUUEZRQSA-N 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000009392 systemic autoimmunity Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000009258 tissue cross reactivity Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- BFFPVEVGHKMWLT-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;3,7-dihydropurin-6-one Chemical compound O=C1NC=NC2=C1NC=N2.O=C1NC(N)=NC2=C1NC=N2 BFFPVEVGHKMWLT-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- 101150107888 AKT2 gene Proteins 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 238000011523 CAR-T cell immunotherapy Methods 0.000 description 1
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 description 1
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 1
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 1
- 101000752037 Homo sapiens Arginase-1 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 1
- 101000896557 Homo sapiens Eukaryotic translation initiation factor 3 subunit B Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 1
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 description 1
- 101001011382 Homo sapiens Interferon regulatory factor 3 Proteins 0.000 description 1
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101001128158 Homo sapiens Nanos homolog 2 Proteins 0.000 description 1
- 101001124991 Homo sapiens Nitric oxide synthase, inducible Proteins 0.000 description 1
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
- 101000584743 Homo sapiens Recombining binding protein suppressor of hairless Proteins 0.000 description 1
- 101000800463 Homo sapiens Transketolase Proteins 0.000 description 1
- 101000800287 Homo sapiens Tubulointerstitial nephritis antigen-like Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 1
- 102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101150100944 Nos2 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 102100035194 Placenta growth factor Human genes 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 102000001218 Rec A Recombinases Human genes 0.000 description 1
- 108010055016 Rec A Recombinases Proteins 0.000 description 1
- 108010006700 Receptor Tyrosine Kinase-like Orphan Receptors Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 101150043341 Socs3 gene Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102000058018 Suppressor of Cytokine Signaling 1 Human genes 0.000 description 1
- 108700027336 Suppressor of Cytokine Signaling 1 Proteins 0.000 description 1
- 102000058015 Suppressor of Cytokine Signaling 3 Human genes 0.000 description 1
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 230000029662 T-helper 1 type immune response Effects 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002604 chemokine receptor CCR2 antagonist Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 230000006690 co-activation Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000011902 gastrointestinal surgery Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000023266 generation of precursor metabolites and energy Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 230000006692 glycolytic flux Effects 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 210000002074 inflammatory monocyte Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 108091073704 let-7c stem-loop Proteins 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 108091005453 macrophage Toll-like receptors Proteins 0.000 description 1
- 108091005446 macrophage receptors Proteins 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 102000007863 pattern recognition receptors Human genes 0.000 description 1
- 108010089193 pattern recognition receptors Proteins 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000012636 positron electron tomography Methods 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 102000035013 scavenger receptor class A Human genes 0.000 description 1
- 108091005451 scavenger receptor class A Proteins 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000013606 secretion vector Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000037455 tumor specific immune response Effects 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001162—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464462—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Definitions
- Cancer describes of a group of diseases which involve unregulated cell growth and death, genome instability and mutations, tumor-promoting inflammation, induction of angiogenesis, immune system evasion, deregulation of metabolic pathways, immortal cell replication, and metastatic tissue invasion [1 ]. Cancer is the second leading cause of death in the United States after heart disease [2]. More than 1 .6 million new cases of cancer are projected to be diagnosed each year, with more than 580,000 Americans expected to die (about 1600 cancer deaths per day), accounting for nearly 1 in 4 of all American deaths [2,3].
- the immune system plays an important role in the development of and progression of cancer.
- Monocytes which differentiate into macrophages, display a variety of responses according to varying stimuli and exhibit different functions depending on the microenvironment surrounding them.
- Macrophages can be pro-inflammatory (M1 ) or anti-inflammatory (M2). Research studies have shown that infiltration of macrophages into the tumor site can account for greater than 50% of the tumor mass, aid in metastasis by inducing angiogenesis, and signify poor prognosis.
- M1 pro-inflammatory
- M2 anti-inflammatory
- TAMs tumor associated macrophages
- Macrophages are cells derived from the myeloid lineage and belong to the innate immune system. They are derived from blood monocytes that migrate into tissue. One of their main functions is to phagocytose microbes and clear cellular debris. They also play an important role in both the initiation and resolution of inflammation [9, 10]. Moreover,
- macrophages can display different responses, ranging from proinflammatory to anti-inflammatory, depending on the type of stimuli they receive from the surrounding microenvironment [1 1 ].
- Two major macrophage phenotypes have been proposed which correlate with extreme macrophage responses: M1 and M2.
- M1 pro-inflammatory macrophages are activated upon contact with certain molecules such as lipopolysaccharide (LPS), IFN- ⁇ , IL-1 ⁇ , TNF- ⁇ , and Toll-like receptor engagement.
- M1 macrophages constitute a potent arm of the immune system deployed to fight infections. They are capable of either direct (pathogen pattern recognition receptors) or indirect (Fc receptors, complement receptors) recognition of the pathogen. They are also armed in their ability to produce reactive oxygen species (ROS) as means to help killing pathogens.
- ROS reactive oxygen species
- M1 macrophages secrete pro-inflammatory cytokines and chemokines attracting other types of immune cells and integrating/orchestrating the immune response. M1 activation is induced by IFN-g, TNFa, GM-CSF, LPS and other toll-like receptors (TLR) ligands,
- M2 anti-inflammatory macrophages also known as IL-2 anti-inflammatory macrophages
- M2 macrophages are activated by anti-inflammatory molecules such as IL-4, IL-13, and IL-10 [12, 13].
- M2 macrophages exhibit immunomodulatory, tissue repair, and angiogenesis properties which allow them to recruit regulatory T cells to sites of inflammation.
- M2 macrophages do not constitute a uniform population and often are further subdivided into M2a, M2b and M2c categories.
- the common denominator of all three subpopulations is high IL-10 production accompanied by low production of IL-12.
- One of their signatures is production of enzyme Arginase-1 that depletes L-arginine thereby suppressing T cell responses and depriving iNOS of its substrate.
- macrophages can exhibit both pro-inflammatory and anti-inflammatory properties, it is important to understand their polarization and function in tumor progression and metastasis.
- Macrophage polarization The tumor microenvironment can affect macrophage polarization.
- the process of polarization can be diverse and complex because of the hostile environment of IL-10, glucocorticoid hormones, apoptotic cells, and immune complexes that can interfere with innate immune cells function [1 1 , 19].
- the mechanisms of polarization are still unclear but it is known they involve transcriptional regulation. For example, macrophages exposed to LPS or IFN- ⁇ will polarize towards an M1 phenotype, whereas macrophages exposed to IL-4 or IL-13 will polarize towards an M2 phenotype.
- LPS or IFN- ⁇ can interact with Toll-like receptor 4 (TLR4) on the surface of macrophages inducing the Trif and MyD88 pathways, inducing the activation of transcription factors IRF3, AP-1 , and N FKB and thus activating TNFs genes, interferon genes, CXCL10, NOS2, IL-12, etc. which are necessary in a pro-inflammatory M1 macrophage response [20].
- TLR4 and IL-13 bind to IL-4R, activation the Jak/Stat6 pathway, which regulates the expression of CCL17, ARG1 , IRF4, IL-10, SOCS3, etc. , which are genes associated with an anti-inflammatory response (M2 response).
- miRNA miRNA
- miRNAs are small non-coding RNA of 22 nucleotides in length that regulate gene expression post-transcriptionally, as they affect the rate of mRNA degradation.
- miRNAs have been shown to be highly expressed in polarized macrophages, especially miRNA-155, miRNA-125, miRNA-378 (M1 polarization), and miRNA let- 7c, miRNA-9, miRNA-21 , miRNA-146, miRNA147, miRNA-187 (M2 polarization) [21 ].
- Macrophage polarization is a complex process where macrophages
- macrophage polarization is better represented by a continuum of activation states where M1 and M2 phenotypes are the extremes of the spectrum.
- M1 and M2 phenotypes are the extremes of the spectrum.
- M1 pro-inflammatory macrophages or classically activated macrophages are aggressive, highly phagocytic, and produce large amounts of reactive oxygen and nitrogen species, thereby promoting a Th1 response [1 1 ].
- M1 macrophages secrete high levels of two important inflammatory cytokines, IL-12 and IL-23.
- IL-12 induces the activation and clonal expansion of Th17 cells, which secrete high amounts of IL-17, which contributes to
- M1 macrophages to control metastasis, suppress tumor growth, and control microbial infections [24]. Moreover, the infiltration and recruitment of M1 macrophages to tumor sites correlates with a better prognosis and higher overall survival rates in patients with solid tumors [17, 18, 25-28].
- Polarization of macrophages to the M1 phenotype is regulated in vitro by inflammatory signals such as IFN- ⁇ , TNF-a, IL-1 ⁇ and LPS as well as transcription factors and miRNAs [29, 30].
- inflammatory signals such as IFN- ⁇ , TNF-a, IL-1 ⁇ and LPS as well as transcription factors and miRNAs [29, 30].
- Cytokine signaling-1 protein functions downstream of cytokine receptors, and takes part in a negative feedback loop to attenuate cytokine signaling.
- Notch signaling plays an important role in the polarization of M1 macrophages, as it allows transcription factor RBP-J to regulate classical activation.
- Macrophages that are deficient in Notch signaling express an M2
- miRNA-155 is upregulated when macrophages are transitioning from M2 to M1 ; M1 macrophages overexpressing miRNA-155 are generally more aggressive and are associated with tumor reduction [33].
- miRNA-342-5p has been found to foster a greater inflammatory response in macrophages by targeting Akt1 in mice. This miRNA also promotes the upregulation of Nos2 and IL-6, both of which act as inflammatory signals for macrophages [34].
- Other miRNAs such as miRNA-125 and miRNA- 378 have also been shown to be involved in the classical activation pathway of macrophages (M1 ) [35].
- M1 macrophages Classically activated macrophages are thought to play an important role in the recognition and destruction of cancer cells as their presence usually indicates good prognosis. After recognition, malignant cells can be destroyed by M1 macrophages through several mechanisms, which include contact-dependent phagocytosis and cytotoxicity (i.e. cytokine release such as TNF-a) [24].
- cytokine release i.e. cytokine release such as TNF-a
- Environmental signals such as the tumor microenvironment or tissue-resident cells, however, can polarize M1 macrophages to M2 macrophages.
- M2 macrophages are anti-inflammatory and aid in the process of
- IL-10 angiogenesis and tissue repair. They express scavenger receptors and produce large quantities of IL-10 and other anti-inflammatory cytokines [33, 36]. Expression of IL-10 by M2 macrophages promotes a Th2 response. Th2 cells consequently upregulate the production of IL-3 and IL-4. IL-3 stimulates proliferation of all cells in the myeloid lineage
- IL-4 is an important cytokine in the healing process because it contributes to the production of the EPO.
- EPO Erythropoietin
- GM-CSF Granulocyte macrophage colony- stimulating factor
- IL-6 IL-6.
- IL-4 is an important cytokine in the healing process because it contributes to the production of the EPO.
- M2 macrophages exhibit functions that may help tumor progression by allowing blood vessels to feed the malignant cells and thus promoting their growth.
- microenvironment helps macrophages maintain an M2 phenotype [23, 39].
- Anti-inflammatory signals present in the tumor microenvironment such as adiponectin and IL-10 can enhance an M2 response [41 ].
- TAMs Tumor associated macrophages
- tumor associated macrophages found in the periphery of solid tumors are thought to help promote tumor growth and metastasis, and have an M2-like phenotype [42].
- Tumor associated macrophages can be either tissue resident macrophages or recruited macrophages derived from the bone marrow (macrophages that differentiate from monocytes to macrophages and migrate into tissue).
- a study by Cortez-Retamozo found that high numbers of TAM precursors in the spleen migrate to the tumor stroma, suggesting this organ as a TAM reservoir also [43].
- angiogenic switch is defined as the process by which the tumor develops a high density network of blood vessels that potentially allows the tumor to become metastatic, and is necessary for malignant transition.
- angiogenic switch is defined as the process by which the tumor develops a high density network of blood vessels that potentially allows the tumor to become metastatic, and is necessary for malignant transition.
- a breast cancer mouse model it was observed that the presence of macrophages was required for a full angiogenic switch.
- angiogenic switch was also delayed suggesting that the angiogenic switch does not occur in the absence of macrophages and that
- the tumor stromal cells produce chemokines such as CSF1 , CCL2, CCL3, CCL5, and placental growth factor that will recruit
- macrophages to the tumor surroundings.
- These chemokines provide an environment for macrophages to activate the angiogenic switch, in which macrophages will produce high levels of IL-10, TGF- ⁇ , ARG-1 and low levels of IL-12, TNF-a, and IL-6.
- the level of expression of these cytokines suggests macrophages modulate immune evasion. It is important to note that macrophages are attracted to hypoxic tumor environments and will respond by producing hypoxia-inducible factor-l a (HIF-1 a) and HIF-2a, which regulate the transcription of genes associated with angiogenesis.
- HIF-1 a hypoxia-inducible factor-l a
- HIF-2a hypoxia-inducible factor-2a
- macrophages can also secrete VEGF (stimulated by the NF- ⁇ pathway), which will promote blood vessel maturation and vascular permeability [48].
- Tumor associated macrophages are thought to be able to maintain their M2-like phenotype by receiving polarization signals from malignant cells such as IL-1 R and MyD88, which are mediated through IkB kinase ⁇ and NF-kB signaling cascade. Inhibition of NF-kB in TAMs promotes classical activation [40]. Moreover, another study suggested that p50 NF-kB subunit was involved in suppression of M1 macrophages, and reduction of inflammation promoted tumor growth. A p50 NF- ⁇ knock-out mouse generated by Saccani et. al suggested that M1 aggressiveness was restored upon p50 NF-kB knockout, reducing tumor survival [49].
- TAMs can be used as a target for cancer treatment.
- TAMs Reducing the number of TAMs or polarizing them towards an M1 phenotype can help destroy cancer cells and impair tumor growth [50-52].
- Luo and colleagues used a vaccine against legumain, a cysteine protease and stress protein upregulated in TAMs thought to be a potential tumor target [52]. When the vaccine against legumain was administered to mice, genes controlling angiogenesis were downregulated and tumor growth was halted [52].
- Metabolic alterations present in tumor cells are controlled by the same genetic mutations that produce cancer [53]. As a result of these metabolic alterations, cancer cells are able to produce signals that can modify the polarization of macrophages and promote tumor growth [54, 55].
- M1 and M2 macrophages demonstrate distinct metabolic patterns that reflect their dissimilar behaviors [56].
- the M1 phenotype increases glycolysis and skews glucose metabolism towards the oxidative pentose phosphate pathway, thereby decreasing oxygen consumption and consequently producing large amounts of radical oxygen and nitrogen species as well as inflammatory cytokines such as TNF-a, IL-12, and IL-6 [56, 57].
- the M2 phenotype increases fatty acid intake and oxidation, which decreases flux towards the pentose phosphate pathway while increasing the overall cell redox potential, consequently upregulating scavenger receptors and immunomodulatory cytokines such as IL-10 and TGF- ⁇ [56].
- Protein kinases such as Akt1 and Akt2, alter macrophage polarization by allowing cancer cells to survive, proliferate, and use an intermediary metabolism [58]. Other protein kinases can direct
- M1 Classically activated (M1 ) macrophages favor inducible nitric oxide synthase (iNOS). The iNOS pathway produces cytotoxic nitric oxide (NO), and consequently exhibits anti-tumor behavior.
- activated (M2) macrophages have been shown to favor the arginase pathway and produce ureum and l-ornithine, which contribute to progressive tumor cell growth [61 , 62].
- CARKL carbohydrate kinase-like protein
- GSH:GSSSG complexes During an M2-like metabolic state,
- macrophages upregulate CARKL and genes regulated by STAT6/IL-4 (IL- 10 and TGF- ⁇ ).
- cancer immunotherapy The role of cancer immunotherapy is to stimulate the immune system to recognize, reject, and destroy cancer cells.
- Cancer immunotherapy with monocytes/macrophages has the goal to polarize macrophages towards a pro-inflammatory response (M1 ), thus allowing the macrophages and other immune cells to destroy the tumor.
- M1 pro-inflammatory response
- Many cytokines and bacterial compounds can achieve this in vitro, although the side effects are typically too severe in vivo. The key is to find a compound with minimal or easily managed patient side effects.
- monocytes/macrophages has been used in past decades and new approaches are being developed every year [64, 65].
- Some approaches to cancer immunotherapy include the use of cytokines or chemokines to recruit activated macrophages and other immune cells to the tumor site which allow for recognition and targeted destruction of the tumor site [67, 68].
- IFN- a and IFN- ⁇ have been shown to inhibit tumor progression by inducing cell differentiation and apoptosis [69].
- IFN treatments are anti-proliferative and can increase S phase time in the cell cycle [70, 71 ].
- Zhang and colleagues performed a study in nude mice using IFN- ⁇ gene therapy to target human prostate cancer cells. Their results indicate that adenoviral-delivered IFN- ⁇ gene therapy involves macrophages and helps suppress growth and metastasis [72].
- the macrophage inhibitory factor is another cytokine that can be used in cancer immunotherapy.
- MIF is usually found in solid tumors and indicates poor prognosis.
- MIF inhibits aggressive macrophage function and drives macrophages toward an M2 phenotype, which can aid tumor growth and progression.
- Simpson, Templeton & Cross (2012) found that MIF induces differentiation of myeloid cells, macrophage precursors, into a suppressive population of myeloid cells that express an M2 phenotype [73]. By targeting MIF, they were able to deplete this suppressive population of macrophages, inhibiting their growth and thus control tumor growth and metastasis [73].
- CCR2 The chemokine receptor type 2, CCR2, is crucial to the recruitment of monocytes to inflammatory sites and it has been shown as a target to prevent the recruitment of macrophages to the tumor site, angiogenesis, and metastasis.
- Sanford and colleagues (2013) studied a novel CCR2 inhibitor (PF-04136309) in a pancreatic mouse model, demonstrating that the CCR2 inhibitor depleted monocyte/macrophage recruitment to the tumor site, decreased tumor growth and metastasis, and increased antitumor immunity [74].
- Schmall et al. showed that macrophages co-cultured with 10 different human lung cancers upregulated CCR2 expression. Moreover, they showed that tumor growth and metastatis were reduced in a lung mouse model treated with a CCR2 antagonist [75].
- Other studies have used liposomes to deliver drugs to deplete M2
- MENK methionine enkephalin
- Bisphosphonates are commonly used to treat metastatic breast cancer patients to prevent skeletal complications such as bone resorption [78]. While bisphosphonates stay in the body for short periods of time, bisphosphonates can target osteoclasts, cells in the same family as macrophages, due to their high affinity for hydroxyapatite. Once bisphosphonates bind to the bones, the bone matrix internalizes the bisphosphonates by endocytosis. Once in the cytoplasm,
- bisphosphonates can inhibit protein prenylation, an event that prevents integrin signaling and endosomal trafficking, thereby forcing the cell to go apoptotic.
- Cationic polymers are used in immunotherapy because of their reactivity once dissolved in water.
- Chen et al. used cationic polymers including PEI, polylysine, cationic dextran and cationic gelatin to produce a strong Th1 immune response [77]. They were also able to induce proliferation of CD4+ cells and secretion of IL-12 typical of M1 macrophages [77].
- Huang and colleagues also used biomaterials to trigger TAMs to produce an anti-tumor response by targeting TLR4 [80]. This study found that TAMs were able to polarize to an M1 phenotype and express IL-12. They found that these cationic molecules have direct tumoricidal activity and demonstrate tumor reduction in mice [80].
- Artificial T cell receptors also known as chimeric T cell receptors, chimeric immunoreceptors, chimeric antigen receptors (CARs) are engineered receptors, which graft an arbitrary specificity onto an immune effector cell. Typically, these receptors are used to graft the specificity of a monoclonal antibody onto a T cell; with transfer of their coding sequence facilitated by retroviral vectors.
- TCR T cell Receptor
- scFv single chain variable fragment
- Chimeric antigen receptors with extracellular antibody fragments directed against a tumor epitope fused to intracellular T-cell signaling domains, have been transduced into T cells, endowing them with a novel specificity toward a non-MHC restricted epitope[3].
- Chimeric antigen receptors are recombinant receptors that provide both surface antigen-binding and T-cell-activating functions. A number of CARs have been reported over the past decade, targeting an array of cell surface tumor antigens. Their biologic functions have dramatically changed following the introduction of tripartite receptors comprising a costimulatory domain, termed second-generation CARs.
- CARs may be combined with costimulatory ligands, chimeric costimulatory receptors, or cytokines to further enhance T-cell potency, specificity, and safety.
- CARs represent a new class of drugs with exciting potential for cancer immunotherapy.
- T cells are capable of inducing potent anti-tumor responses, however, T cells that would most efficiently respond to peptide-MHC epitopes on the surface of tumors are often subjected to clonal tolerance or deletion, as many of these epitopes are very similar or identical to self-epitopes.
- T-cell therapies have involved genetic modification of T cells in vitro by introduction of TCRs against tumor-associated T-cell epitopes. This strategy has shown promise, but various challenges surrounding T-cell epitopes in general, as well as potential mispairing of introduced TCR with endogenous TCR, remain. There are proposals to harness the power of T cells in the fight against tumors, by allowing T cells to respond to traditional antibody epitopes.
- BiTEs bispecific T-cell engagers
- bispecific antibody which links an anti-cancer antibody with an antibody recognizing CD3 subunits.
- BiTEs bispecific T-cell engagers.
- a single-chain variable fragment (scFv) that binds a tumor epitope is linked to a second scFv that binds an invariant portion of the T- cell receptor complex, resulting in activation and targeting of effector T cells against the tumor epitope, regardless of the TCR-mediated specificity of the T cells.
- BiTEs have been constructed targeting more than ten tumor associated epitopes, including blinatumomab against CD19 (for B cell leukemias), and MT-1 10 against EpCAM (for various adenocarcinomas and cancer stem cells), both being currently evaluated in clinical trials. High response rates for relapse-free survival and elimination of minimal residual disease were found in refractory acute lymphoblastic leukemia (ALL) patients receiving blinatumomab in clinical trials.
- ALL acute lymphoblastic leukemia
- TK1 Human Thymidine Kinase 1
- sTK serum of cancer patients
- TK1 levels in primary breast tumors can be used to predict recurrence.
- Other exciting TK1 prognostic studies show significant reductions in sTK1 levels when patients respond to treatment while sTK1 levels continue to rise in patients who do not appear to respond to their treatment. It is also known that sTK1 levels begin to rise prior to recurrence and noted in some cases sTK1 levels could predict recurrence "1 -6 months before the onset of clinical symptoms”.
- HSV-TK has been used in gene therapy and PET imaging utilizes TK1 to identify proliferating cancer cells
- TK1 The diagnostic and prognostic potential of TK1 has been demonstrated using the traditional TK activity radioassay for both haematological malignancies and solid tumors. TK1 has been extensively studied in the context of cancer diagnostic biomarkers, where it has been shown to be upregulated in tissue and serum in both solid tumors and haematological malignancies.
- TK1 levels in serum have also been shown to have diagnostic potential in other cancers such as bladder, cervical carcinoma, gastric, non-small cell lung, and renal and colorectal cancers.
- high TK1 serum levels correlate with tumor aggressiveness and can be indicative of early events in carcinogenesis.
- the mechanism by which TK1 enters the serum and its function in the serum has been largely unexplored. Perhaps, its function in the serum is connected to regulating the immune system. Further analyses are needed to understand this connection and its significance.
- TK1 adopts a variety of oligomeric forms although it is most commonly found as a dimer or tetramer, approximately 53 kDa and 100 kDa respectively.
- Munch-Petersen reported that the TK1 dimer was the low- efficiency form of the enzyme with a high Km (15 ⁇ ).
- the TK1 tetramer was a high- efficiency form with a low Km (0.7 ⁇ ) and was reported to have 30-fold increased efficiency compared to the dimer in catalyzing its phosphoryl transfer reaction. The crystallization of TK1 indicates that the tetrameric form is composed of a dimer of dimers.
- TK1 Thymidine kinase 1
- nucleotides are either synthesized de novo or through the salvage pathway where they are recycled from intracellular and extracellular sources.
- TK1 is one of two major salvage pathway kinases responsible for
- TK1 is primarily responsible for the phosphorylation of deoxythymidine (dT). Its product, dTMP, is then subsequently phosphorylated and incorporated into the DNA as deoxythymidine triphosphate (dTTP). Expectedly, dTTP helps to regulate this process as it inhibits TK1 , the rate-limiting step of this process. Under normal proliferating conditions, TK1 is regulated by the cell cycle. TK1 levels are very low or barely detectable during G1 phase and begin to increase during late G1 phase. TK1 levels peak during S phase at concentrations near 200 nM, at least 10- fold higher than levels during G1 phase. Interestingly, Sherley et al.
- TK1 mRNA only increased 3-fold or less, compared to the 15-fold increase in protein activity levels, during the cell cycle. They also determined that the rate of [35S] incorporation during S phase was 12-fold more efficient than during the G1 phase. Indicating that the rapid increase in TK1 levels during S phase was a result of an increase in the efficiency of TK1 translation, rather than an increase in transcription. This finding is particularly interesting in light of a study by Chou et al. in which a 5'- untranslated region (5'UTR) allowed translation of TK1 mRNA to be cap- independent. Munch-Peterson et al. has since demonstrated that this rapid increase in TK1 is also a result of conversion from an inactive dimeric to the active tetrameric TK1 form.
- TK1 levels increase as a result of DNA damage, especially following irradiation or chemotherapy.
- Chen et al. further characterized the connection between TK1 and DNA damage by showing p53-/- tumor cells increased TK1 levels in response to DNA damage while p53 wildtype tumor cells did not.
- This connection between TK1 and p53 has been corroborated in other studies which report normal p53 function is required to maintain cell cycle dependent regulation of TK1 , and upon p53 loss, there is a compensatory increase in TK1 . Closer analysis of this connection revealed that the increase in TK1 levels following DNA damage is dependent on p21 .
- TK1 knockdown did not affect the growth of tumor cells, even though the levels of dTTP significantly decreased (p ⁇ 0.01 ).
- TK1 is responsible for maintaining the dTTP nucleotide pool in a cell cycle-dependent manner. Additionally, TK1 plays an invaluable role in DNA repair and survival of tumor cells following DNA damage. The biological significance of TK1 is less understood and somewhat puzzling.
- TK1 function is essential for proper development and function of the kidney and salivary gland although these mechanisms are not understood. TK1 also appears to be necessary for the normal function of the immune system and may play a role in its deregulation. Another unexplored and puzzling function of TK1 is its role in the circulatory system of cancer patients.
- HGPRT or HPRT is a crucial enzyme for the large-scale production of Guanine and Inosine bases. HPRT functions by transferring
- Hypoxanthine-guanine phosphoribosyltransferase is an enzyme encoded in humans by the HPRT1 locus. This enzyme that allows cells to recycle purines, a type of building block of DNA and its chemical cousin RNA. Manufacturing purines uses more energy and takes more time than recycling purines, which makes recycling these molecules more efficient. Recycling purines ensures that cells have a plentiful supply of building blocks for the production of DNA and RNA. The process of recycling purines is also known as the purine salvage pathway.
- HPRT Hypoxanthine Guanine Phosphoribosyltransferase
- HGPRT Hypoxanthine Guanine Phosphoribosyltransferase
- HGPRT Hypoxanthine Guanine Phosphoribosyltransferase
- PRPP Hypoxanthine Guanine Phosphoribosyltransferase
- PPi pyrophosphate
- HGPRT will transfer the ribose monophosphate from PRPP to a hypoxanthine base to form IMP.
- This enzyme transfers phosphoribose from PRPP to hypoxanthine or guanine bases (Stout & Caskey, 1985; Wilson, Tarrt, & Kelley, 1983).
- the HGPRT enzyme is composed of ten beta strands and six alpha helices with residues 37-189 forming the core of the enzyme (Eads, Scapin, Xu, Grubmeyer, &
- the protein can exist as either a dimer or a tetramer with identical subunits (Eads et al., 1994; Keough, Brereton, De Jersey, & Guddat, 2005; Zhang et al., 2016).
- the molecular weight of each of the protein subunits is 48.8783 kDa and the molecule has an instability index of 21 .69, which classifies the protein as stable.
- the homo tetramer contains four subunits labeled A, A', B, and B' (Eads et al., 1994).
- Shown in FIGURE 8 is the HGPRT biochemical pathway.
- the homo tetramer structure of human HGPRT has beta sheets, beta strands, alpha helices, and beta turns.
- the protein has only 27% alpha helices and 27% beta sheets, which indicates that the remaining 46% of the enzyme are beta turns and random coils.
- the structure has subunits labeled, A, A ' and B, B'. Each subunit is relatively identical and is translated from the same mRNA message.
- the enzyme has several regions that each have distinct functions in
- the carboxy terminal end of the central beta sheet is primarily involved in substrate recognition.
- the core region of the protein contains twisted parallel beta sheets with five beta strands that are surrounded by four alpha helices.
- Resides 65-74 form the most flexible portion of the protein as they create a loop that will bind pyrophosphate.
- the residues of the enzyme that will bind PRPP substrate are 129-140, which are located on the floor of the active site.
- the metal ion Mg 2+ is required (Eads et al., 1994; Zhang et al., 2016).
- HPRT The gene that encodes HGPRT is called HPRT.
- This 47,827bp gene resides on the long arm of the X chromosome and is relatively large, especially considering that only a small portion of the transcribed DNA is eventually translated.
- the gene contains 9 exons that code for a 217 amino acid protein, which represents only 1 .3% of the original genomic message (Fuscoe, Fenwick, Ledbetter, & Caskey, 1983; Stout & Caskey, 1985; Wilson et al., 1983).
- HPRT is found in all somatic tissue in low levels (Melton, Mcewan, Reid, & Mckie, 1986). In a majority of human cells
- HPRT mRNA transcripts comprise only 0.005 to 0.01 % of the total mRNA (Caskey, 1981 ). The only exception is in central nervous tissue where there is an unusually elevated level of HPRT expression ranging from 0.02 to 0.04% of the total mRNA, which is a 4 fold increase in comparison to other somatic tissue (Caskey, 1981 ; Zoref-shani, Frishberg, & Bromberg, 2000). This elevated expression is not fully understood because cells in the central nervous system (CNS) are not stimulated to divide and would therefore require less machinery for nucleotide synthesis.
- CNS central nervous system
- the human genome contains non-functional HPRT homologous regions in the autosomal DNA of chromosomes 5, 1 1 , and 13 (Fuscoe et al. , 1983). These DNA sequences are not known to be transcribed and are most likely pseudogenes, but their exact origin and expression is not well understood (Nyhan & Diego, 2012).
- HPRT would be upregulated in these environments (Linehan & Goedegebuure, 2005).
- Linehan & Goedegebuure, 2005 Through preliminary studies to determine whether HPRT is upregulated in a cancerous setting, it has been determined that there is a strong association between HPRT and the plasma membrane of cancer cells. This association has been observed in a variety of cancer types and cell lines with multiple different assays. Confocal images and flow cytometry analysis have been obtained for multiple different cancer cell lines and show that HPRT is consistently expressed on the surface of all cancer types tested. This same expression is not observed for the salvage pathway enzymes DCK and APRT, indicating that HPRT has a role in a cancerous environment that is not shared by all salvage pathway enzymes.
- Macrophages [0070] An aspect is the use of modified macrophages against the cancer
- macrophages have antigen receptors against cancer antigens.
- T-cells with antigen receptors against cancer antigens have been used to develop T-cells with antigen receptors against cancer antigens. These antigens are often substances that in normal condition don't activate an immune response, because they are identical or similar to human-produced substances. For this reason, T-cells have been modified to have such receptors. Therapies have been studied that involve such T-cells with chimeric antigen receptors (CAR), where the antigen receptors are directed against a tumor epitope. The T cells are capable of inducing potent anti-tumor responses, as noted in the Background above, these therapies are promising, but there are problems that have appeared.
- CAR chimeric antigen receptors
- T-cell therapies have involved genetic modification of T cells in vitro by introduction of TCRs against tumor-associated T-cell epitopes. This strategy has shown promise, but various challenges surrounding T-cell epitopes in general, as well as potential mispairing of introduced TCR with endogenous TCR, remain.
- T-cells can be long-lived and be present indefinitely in the in the body, and can also be antigen-experienced against the cancer antigen. This means that T-cells that are antigen-specific against the tumor antigen marker can be present after the therapy treatment and elimination of the cancer. This can be a problem because the tumor-antigens are usually human created (necessitating the CARs in the first place) and may be present in small amounts for different body functions. Continued existence of the modified CAR T-cells and the potential innocent occurrence of the target antigen may result in harmful and unwanted activation of the T-cells.
- cytokine storm This may compromise an important process in the body, or lead to a cytokine storm, where breakdown of the cytokine production/activation feed-back loop for T-cells results in uncontrolled and ballooning activation of immune cells, resulting in a massive immune response.
- a cytokine storm can do significant damage and potentially result in death.
- Macrophage CAR Macrophage CAR
- Macrophage cells although they may last several weeks after an infection, and do not appear to possess memory, unlike CAR T cells. Accordingly, potential harm from a response to innocent low concentrations of the cancer antigen by lingering CARs will diminish.
- macrophages do not participate in the cytokine storm
- Antigens Associated with Cancers An aspect of the present therapy is that certain cancer and tumor antigens are associated with cancers and tumors, and are not associated with noncancerous tissues. For example, It has been demonstrated that TK1 and HGPRT are expressed on the surfaces of many, and likely all, cancerous types, with little or no expression on the surface of normal cells. These provide an antigen marker that allows a therapy to detect and target cancer cells, and kill the cancerous cells without harming non-cancerous cells.
- An aspect is the use of monocytes/macrophages to combat cancer by combining modified macrophage-specific CAR technology and
- human/humanized antibodies against human thymidine kinase 1 (TK1 ) and Hypoxanthine-guanine phosphoribosyS transferase (HPRT). It also includes the use of humanized antibodies against other common tumor targets such as CD19, CD20, epidermal growth factor (EGFR), receptor tyrosine kinase-like orphan receptor 1 (ROR1 ) and other novel tumor targets to produce a macrophage potentially activated against many different tumors.
- TK1 human thymidine kinase 1
- HPRT Hypoxanthine-guanine phosphoribosyS transferase
- CD19, CD20 epidermal growth factor
- EGFR epidermal growth factor
- ROR1 receptor tyrosine kinase-like orphan receptor 1
- additional potential antigen markers that can be used by the present therapy system to target cancer cells over normal cells. These may include, for example, salvage pathway enzymes, substance that contribute to metastasis such as
- any normal antigen that is not found on the surface of normal cells but may be expressed on the surface of cancer cells any mutated normal human protein that may be significantly different from normal protein so as to be distinguished by CAR or MOTO CAR.
- Some fetal antigens that may be expressed exclusively on cancer cells, mutated proteins produced as a result of tumor formation may also be used as targets if they are sufficiently different from the non-mutated protein so as to be distinguished by antibodies.
- TK1 and HPRT are up regulated in many forms of cancer and have been found on the surface of many cancer cells. Neither is found on the surface of normal cells and therefore is a prime target for immunotherapy.
- Preliminary findings indicate that HGPRT is on the surface in the same proportion as TK1 i.e. if TK1 is high HGPRT is also high, if TK1 is low HGPRT is also low. While not being bound to a theory, they may be complexed together.
- the present technology contemplates the use of a CAR or BiTE produced with a scFv from a humanized or non-human mammal (such as mouse) monoclonal antibody to HGPRT or TK1 , that could be used with
- the uniqueness of the present technology lies in part in the fact that using specifically generated antibodies to human cancer antigens that are associated with cancer cells and not normal cells can be used to target tumors.
- antigens expressed in this manner on the surface of the cancer cell like TK1 and HGPRT can be used to target CARs, MOTO CARs and BiTEs to the tumors.
- Antibodies specific to human HGPRT are known, such as at
- Antibodies specific to human TK are known, such as disclosed in United States Patents 9267948, 7837998, 7311906, and 5698409
- An aspect is using a macrophage or a monocyte or other immune cell containing a MOTO-CAR Vector (scFV fused to a Toll like receptor intracellular activating region) designed against as specific tumor associated antigen, and using monocytes or macrophages and a MOTO- CAR technology against tumors or other diseases. The technology could be used against any specific antigen using vectors to illicit an immune response utilizing monocytes or macrophages.
- An aspect is using a macrophage or a monocyte or other immune cell containing a MOTO-CAR Vector (scFV fused to a Toll like receptor intracellular activating region) designed against as specific tumor associated antigen such as TK1 and HPRT.
- An aspect is a method for treating tumors where the specific tumor antigen is in particular HPRT.
- TK1 has high levels in serum from patients with aggressive tumors this could bind to the MOTO-CAR and activate the CAR before it gets to the tumor site.
- HPRT has been shown to have low serum levels and also seems to be more abundantly dispersed on the cancer cell membranes and not on normal cells.
- An aspect is a method for polarizing macrophages to an M1 phenotype in a cancerous environment. The MOTO-CAR is designed to attach to TK1 or HPRT on the surface of cancer cells and activate the macrophage converting it to a M1 aggressive killing macrophage as opposed to the M2 that associates with the tumor and protects it from immune destruction.
- An aspect is use of macrophage specific promoter for macrophage CAR activation. Since the MOTO-CAR may bind soluble TK1 in the serum it could activate without being near the tumor. A possible solution to this is to separate monocytes from the patient and infect them with a MOTO- CAR construct that will be under the control of a macrophage specific promoter. Monocytes only become macrophages when they move from the blood to the tissues. Having the MOTO-CAR under the control of a macrophage specific promoter will allow the MOTO-CAR only to be expressed in tissue and thereby avoid the problems with activation in serum. [0089] Another aspect is utilizing cytoplasmic macrophage activating molecules/ signaling cascades such as Toll like receptors.
- the MOTO-CAR may be activated by utilizing the Toll like receptor cytoplasmic domain.
- activating signaling molecules that can have a similar function.
- a different activating molecule is contemplated.
- the molecule used does not have to be a Toll like Receptor there are other signaling pathways that could utilize this technology.
- Another aspect involves utilizing an scFv derived from a
- scFv's from mouse or human are contemplated.
- MOTO-CAR with scFv's from both mouse and human, or obtaining human antibodies against
- TK1 and HPRT using a yeast library that produces human monoclonal antibodies using a yeast library that produces human monoclonal antibodies.
- MOTO-CAR technology may not be limited to attacking cancer, and there may be other diseases where this technology could be effective.
- Another aspect is use of co-stimulatory molecules to enhance the
- BIME bispecific macrophage engagers
- BIMEs Bispecific Macrophage Engagers
- the first is a molecule composed of a molecule of IFN- ⁇ linked by an amino acid spacer to any ScFv against TK1 , HPRT or any other tumor antigen.
- the second is designed by the union of a ScFv against the CSF-1 receptor and a ScFv against a tumor antigen.
- the third involves a bispecific antibody against the hydrophobic pocket of the
- MD2 protein which brings in close activation proximity two TLR4 proteins triggering the signaling cascade by the physical encounter of the two TLR4s's TIR domains in the cytosol.
- MOTO-CARS and BIMES are part of the new generation of cancer immunotherapy technologies and both of them could be used to in the treatment of many different cancer types.
- Figure 1 is a schematic illustrating a macrophage chimeric antigen
- Figure .2 is a schematic showing a Macrophage Toll-like receptor CAR.
- MOTO CAR The intracellular domain and transmembrane domain of Toll like receptors, FC-gamma III receptor, IL-1 or the IFN-gamma receptors can be fused to a suitable hinge and a ScFv against a tumor antigen to activate Macrophages upon binding to a specific tumor antigen.
- Figure 3a is a schematic showing different macrophage receptors that could be utilized to build a macrophage CAR.
- Figure 3b is a schematic showing signaling of Fc Gamma Receptor III
- FIG 4 is a schematic showing where Bispecific Macrophage Engagen F N- Y (B IMEIFN-Y)- M2 tumor resident macrophages can be polarized and anchored to tumor cells using a molecule of IFN- ⁇ linked by a aminoacid spacer to a ScFv against a tumor antigen.
- Figure 5 is a schematic showing where Bispecific Macrophage Engager (BIME). M2 macrophages can be polarized towards M1 phenotype and directed to tumor cells.
- a bispecific antibody can block CSF-1 receptor blocking CSF-1 a receptor that leads to an M2 profile
- the macrophage can be anchored with a ScFv against a tumor antigen. The patient then can receive IFN- ⁇ and the macrophage can be polarized towards a M1 phenotype for tumor elimination.
- FIG. 6 is a schematic showing Macrophage Activator M D2 (BIME M D2)-
- Toll-like receptor 4 dimerization can be triggered by using a ScFv against the hydrophobic pocket of the MD2 protein. Then a BIME can be added to anchor macrophages to the tumor cells.
- Figure 7 is a schematic illustrating Toll Like Receptor Signaling
- FIG. 8 is shown the HGPRT biochemical pathway
- Figure 9 is a graph illustrating HGPRT protein surface expression
- TK1 and HPRT are exclusively expressed on the surface membrane of tumor cells and have led to the development of a range of monoclonal antibodies against human TK1 and HPRT.
- the specific binding capacity of these specific monoclonal antibodies could be used in macrophages transfected with a modified macrophage-specific chimeric antigen receptor to treat cancer patients.
- a method for modifying a monocyte/macrophage to have receptors against human TK1 might include producing human/humanized monoclonal antibodies that are TK1 and
- FIGURE 1 HPRT specific (FIGURE 1 ). These TK1 and HPRT specific monoclonal antibodies would be used to create chimeric antigen receptors (CARs) by fusion of the single-chain variable fragments to macrophage (MO) signaling domains (FIGURE 2) (such as the cytoplasmic domain portion from a toll-like receptor (TO), the FC gamma III, IL-1 or INF-gamma receptors) (FIGURE 7) that would be transduced into the macrophage (FIGURE 3a, b).
- MO macrophage
- FIGURE 7 chimeric antigen receptors
- monocytes/macrophages would be removed from the patient and transfected ex vivo with a macrophage- specific chimeric antigen receptor lentiviral vector.
- cDNA was purified from a monoclonal antibody hybridoma cell (CB1 ) with an antibody specific to human TK1 and used to amplify the heavy and light chains of the CB1 variable region via polymerase chain reaction (PCR) Sequences from the heavy and light chain were confirmed using NCBI Blast. CB1 heavy and light chains were fused together via site overlap extension (SOE) PCR to make a single chain fragment variable (scFv) using a G4S linker.
- SOE site overlap extension
- scFv single chain fragment variable
- the G4S linker was codon optimized for yeast and humans using the Codon Optimization tool provided by IDT
- TK-1 and HPRT-specific human scFv antibodies were isolated from a yeast antibody library. TK-1 and HPRT protein was isolated, His-tagged, and purified. TK-1 and HPRT protein was labeled with an anti-His biotinylated antibody and added to the library to select for TK-1 and
- HPRT-specific antibody clones TK-1 and HPRT antibody clones were alternately stained with streptavidin or anti-biotin microbeads and enriched using a magnetic column. Two additional rounds of sorting and selection were performed to isolate TK-1 and HPRT specific antibodies. For the final selection, possible TK-1 and HPRT antibody clones and their respective protein were sorted by fluorescence-activated cell sorting (FACS) by alternately labeling with fluorescently-conjugated anti-HA or anti-c-myc antibodies to isolate TK-1 and HPRT specific antibodies. High affinity clones were selected for CAR construction. Other human antibodies or humanized antibodies from other animals could be selected or altered to be TK-1 or HPRT specific by using phage display or other recombination methods.
- FACS fluorescence-activated cell sorting
- the antibody construct was inserted into the pPNL9 yeast secretion vector and YVH10 yeast were transformed with the construct and induced to produce the antibody.
- Other expression systems such as E. coli or mammalian systems could also be used to secrete antibodies.
- humanized or non-human mammal such as mouse
- monoclonal antibody to HPRT and TK1 that could be used with appropriate genetic
- HPRT and TK1 are on the surface of cancer cells and not on the surface of any normal cell is a major part of the discovery, as this knowledge can be used to allow lymphocytes to be directed specifically to the tumor cells.
- HPRT and TK1 are expressed on the surface of human cancer cells and are believed not to be on the surface of normal cells and thereby can be used to target CARs and BiTEs to the tumors.
- T cells have been used extensively in CAR therapy with varying results it is also proposed to use genetically modified macrophages using scFv from unique antibodies attached to a cytoplasmic domain of a Toll Like receptor such as Toll like receptor 4 to activate macrophages against tumors.
- This unique approach overcomes many of the inherent problems associated with the current T cell CAR technology. Utilizing the killing power of macrophages directed at specific unique targets on tumor cells allows for the enhanced response without the major drawbacks such as cytokine storm, memory activation, and on target off target problems.
- An aspect is to couple the potential of a specific monoclonal antibody
- This application is to protect the technology that would allow the use of a CAR or BiTE produced with a scFv from a humanized or mouse monoclonal antibody to HPRT, TK1 or other tumor antigen, that could be used with appropriate genetic engineering to manipulate macrophages, neutrophils or other immune cells ultimately from a patient but not limited to such, to treat a disease such as cancer.
- the scFv from the humanized mouse monoclonal would be engineered to attach to the transmembrane and cytoplasmic domain of the TLR4, resulting in a TLR4 macrophage chimeric antigen receptor. That fact that HPRT is on the surface of cancer cells and not on the surface of any normal cell is a major part of the discovery, as this knowledge and these techniques can be used to allow the macrophages to be directed, (using the HPRT
- Immunotherapy requires the activation of the immune system however it is difficult to find a cytokine, chemokine, compound, or biomaterial that will not produce some side effects.
- Macrophages belong to the innate immune system and exhibit pro- inflammatory and anti-inflammatory properties, they are the ideal im m unotherapy cand idates.
- Macrophage polarization tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology, 23(1 1 ), 549-55. Retrieved from
- tumour-associated macrophages in tumour progression: implications for al of Pathology, 196(3), 254-
- Tumor necrosis factor a potent effector molecule for tumor cell killing by activated macrophages.
- microRNA-342- 5p fosters inflammatory macrophage activation through an Akt1 - and microRNA-155-dependent pathway during atherosclerosis.
- bromopyruvate hexokinase 2 inhibitor
- Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human
- CARKL directs macrophage polarization through control of glucose metabolism. Cell Metabolism, 15(6), 813-26.
- IL-4 interleukin-4
- STAT6 protein signaling axis in obesity.
- Macrophage Migration Inhibitory Factor Promotes Tumor Growth and Metastasis by Inducing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. The Journal of Immunology.
- Lymphocyte in vitro cytotoxicity characterization of human lymphotoxin. Proceedings of the National Academy of Sciences of the United States of America, 1250-1255. Retrieved from
- CARs CAR Receptors
- BiTEs Bispecific T -cell engagers
- Garrido F Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL.
- Macrophage Polarisation an Immunohistochemical Approach for Identifying M1 and M2 Macrophages. PloS One, 8(1 1 ), e80908.
- Class A scavenger receptor attenuates myocardial infarction-induced cardiomyocyte necrosis through suppressing M1 macrophage subset polarization.
- Lymphocyte in vitro cytotoxicity
- Macrophage polarization tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology, 23(1 1 ),
- Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival.
- Macrophage Migration Inhibitory Factor Promotes Tumor Growth and Metastasis by Inducing Myeloid-Derived Suppressor Cells in the Tumor
- Tumor necrosis factor a potent effector molecule for tumor cell killing by activated macrophages. Proceedings of the National Academy of Sciences of the United States of America, 83(14), 5233-7. Retrieved from
- Van Ginderachter J. A., Movahedi, K., Hassanzadeh Ghassabeh, G., Meerschaut, S., Beschin, A., Raes, G., & De Baetselier, P. (2006).
- Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. The Journal of
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201890489A EA201890489A1 (en) | 2015-08-13 | 2016-10-13 | CAR MACROPHAGES (MOTO-CAR) IN IMMUNOTHERAPY |
PCT/IB2016/056140 WO2017025944A2 (en) | 2015-08-13 | 2016-10-13 | Macrophage car (moto-car) in imunotherapy |
EP16801306.8A EP3334764A2 (en) | 2015-10-13 | 2016-10-13 | Macrophage chimeric antigen receptor (moto-car) in imunotherapy |
AU2016305353A AU2016305353B2 (en) | 2015-08-13 | 2016-10-13 | Macrophage chimeric antigen receptor (MOTO-CAR) in imunotherapy |
CN201680059778.7A CN108137704A (en) | 2015-10-13 | 2016-10-13 | Macrophage CAR in immunotherapy(MOTO-CAR) |
CA2998406A CA2998406A1 (en) | 2015-08-13 | 2016-10-13 | Macrophage car (moto-car) in immunotherapy |
KR1020187007097A KR20180054600A (en) | 2015-10-13 | 2016-10-13 | The macrophage chimeric antigen receptor (MOTO-CAR) |
US15/358,395 US11352439B2 (en) | 2015-08-13 | 2016-11-22 | Macrophage CAR (MOTO-CAR) in immunotherapy |
ZA2018/01636A ZA201801636B (en) | 2015-08-13 | 2018-03-09 | Macrophage chimeric antigen receptor (moto-car) in imunotherapy |
US17/833,149 US20220372170A1 (en) | 2015-08-13 | 2022-06-06 | Macrophage CAR (MOTO-CAR) In Immunotherapy |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62/204,935 | 2015-08-13 | ||
US201562240528P | 2015-10-13 | 2015-10-13 | |
US62/240,528 | 2015-10-13 | ||
US201615236421A | 2016-08-13 | 2016-08-13 | |
US15/236,421 | 2016-08-13 | ||
PCT/IB2016/056140 WO2017025944A2 (en) | 2015-08-13 | 2016-10-13 | Macrophage car (moto-car) in imunotherapy |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US201615236421A Continuation-In-Part | 2015-08-13 | 2016-08-13 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US201615236421A Continuation | 2015-08-13 | 2016-08-13 | |
US15/358,395 Continuation US11352439B2 (en) | 2015-08-13 | 2016-11-22 | Macrophage CAR (MOTO-CAR) in immunotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2017025944A2 true WO2017025944A2 (en) | 2017-02-16 |
WO2017025944A3 WO2017025944A3 (en) | 2017-04-27 |
Family
ID=62299116
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2016/056140 WO2017025944A2 (en) | 2015-08-13 | 2016-10-13 | Macrophage car (moto-car) in imunotherapy |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3334764A2 (en) |
KR (1) | KR20180054600A (en) |
CN (1) | CN108137704A (en) |
WO (1) | WO2017025944A2 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018212770A1 (en) * | 2017-05-17 | 2018-11-22 | Thunder Biotech Inc. | Transgenic macrophages, chimeric antigen receptors, and associated methods |
US10415017B2 (en) | 2017-05-17 | 2019-09-17 | Thunder Biotech, Inc. | Transgenic macrophages, chimeric antigen receptors, and associated methods |
WO2020048341A1 (en) * | 2018-09-04 | 2020-03-12 | 华瑞同康生物技术(深圳)有限公司 | Mammalian cell recombinant anti-human tk1 monoclonal antibody of chicken origin, single-chain antibody, preparation method therefor and application thereof |
WO2020176605A1 (en) * | 2019-02-26 | 2020-09-03 | The University Of Vermont And State Agricultural College | Antibodies to neoantigens and uses thereof |
WO2021119538A1 (en) * | 2019-12-11 | 2021-06-17 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods for manufacture and uses thereof |
US11052138B2 (en) | 2015-05-20 | 2021-07-06 | Thunder Biotech Inc. | Use of car and bite technology coupled with an SCFV from an antibody against human thymidine kinase 1 to specifically target tumors |
US11352439B2 (en) | 2015-08-13 | 2022-06-07 | Kim Leslie O'Neill | Macrophage CAR (MOTO-CAR) in immunotherapy |
WO2022248602A1 (en) * | 2021-05-25 | 2022-12-01 | Institut Curie | Myeloid cells overexpressing bcl2 |
US11517589B2 (en) | 2015-02-19 | 2022-12-06 | Myeloid Therapeutics, Inc. | Chimeric antigen receptor dendritic cell (CAR-DC) for treatment of cancer |
EP3962497A4 (en) * | 2019-04-30 | 2023-01-18 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
US11628218B2 (en) | 2020-11-04 | 2023-04-18 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
US11655282B2 (en) | 2016-09-27 | 2023-05-23 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
US11672874B2 (en) | 2019-09-03 | 2023-06-13 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
US11708423B2 (en) | 2017-09-26 | 2023-07-25 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules and methods of use |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3328402A4 (en) | 2015-07-28 | 2019-04-03 | The Trustees Of The University Of Pennsylvania | Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof |
CN112567026A (en) * | 2018-07-19 | 2021-03-26 | 昂科霍斯特公司 | IL-31 improves the efficacy of macrophage-based adoptive cell therapy for cancer |
JP6935383B2 (en) * | 2018-09-27 | 2021-09-15 | 公益財団法人実験動物中央研究所 | Immunodeficient mouse |
CN109266618B (en) * | 2018-10-18 | 2021-04-23 | 赛元生物科技(杭州)有限公司 | Macrophage capable of targeting tumor cells and preparation method thereof |
BR112022024228A2 (en) | 2020-06-04 | 2023-02-07 | Carisma Therapeutics Inc | CONSTRUCTS FOR CHIMERIC ANTIGEN RECEPTORS |
CN111925448B (en) * | 2020-08-03 | 2022-06-21 | 山东大学 | Preparation method of in vivo-generated CAR-macrophage and application of in vivo-generated CAR-macrophage in tumor immunotherapy |
WO2022186625A1 (en) * | 2021-03-03 | 2022-09-09 | 서울대학교산학협력단 | Method for producing chimeric antigen receptor-macrophages and use of same cells |
KR20220131801A (en) | 2021-03-22 | 2022-09-29 | 주식회사 이뮤노로지컬디자이닝랩 | Transformed professional antigen presenting cells specifically binding to antigen containing chimeric antigen receptor(CAR) and uses thereof |
KR20220132401A (en) | 2021-03-23 | 2022-09-30 | 주식회사 이뮤노로지컬디자이닝랩 | Transformed professional antigen presenting cells specifically binding to antigen containing chimeric antigen receptor(CAR) and uses thereof |
CN115011561A (en) * | 2022-06-22 | 2022-09-06 | 深圳先进技术研究院 | Chimeric antigen receptor macrophage and preparation method and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698409A (en) | 1993-08-06 | 1997-12-16 | Brigham Young University | Monoclonal antibodies to thymidine kinase 1 and uses in diagnostic and therapeutic applications |
US7311906B2 (en) | 2004-04-30 | 2007-12-25 | Brigham Young University | Anti-viral activity of an anti-thymidine kinase monoclonal antibody |
US7837998B2 (en) | 2004-05-21 | 2010-11-23 | Nathaniel Lallatin | Anti-cancer activity of an anti-thymidine kinase monoclonal antibody |
US9267948B2 (en) | 2009-12-30 | 2016-02-23 | Brigham Young University | Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100143290A1 (en) * | 2008-12-04 | 2010-06-10 | Lallatin Nathaniel C | Monoclonal antibodies to human thymidine kinase to treat cancer |
WO2015063069A1 (en) * | 2013-10-28 | 2015-05-07 | Benjamin Felder | Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors |
CN104910279B (en) * | 2015-06-05 | 2019-02-22 | 重庆精准生物技术有限公司 | Target Chimeric antigen receptor, the Lentiviral and its preparation method and application of carcinomebryonic antigen |
-
2016
- 2016-10-13 CN CN201680059778.7A patent/CN108137704A/en active Pending
- 2016-10-13 KR KR1020187007097A patent/KR20180054600A/en not_active Application Discontinuation
- 2016-10-13 EP EP16801306.8A patent/EP3334764A2/en not_active Ceased
- 2016-10-13 WO PCT/IB2016/056140 patent/WO2017025944A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698409A (en) | 1993-08-06 | 1997-12-16 | Brigham Young University | Monoclonal antibodies to thymidine kinase 1 and uses in diagnostic and therapeutic applications |
US7311906B2 (en) | 2004-04-30 | 2007-12-25 | Brigham Young University | Anti-viral activity of an anti-thymidine kinase monoclonal antibody |
US7837998B2 (en) | 2004-05-21 | 2010-11-23 | Nathaniel Lallatin | Anti-cancer activity of an anti-thymidine kinase monoclonal antibody |
US9267948B2 (en) | 2009-12-30 | 2016-02-23 | Brigham Young University | Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof |
Non-Patent Citations (179)
Title |
---|
"Structural Consensus among Antibodies Defines the Antigen Binding Site", PLOS COMPUT BIOL, vol. 8, no. 2, pages E1002388 |
ALEGRE. M; ROBISON, R.A; O'NEILL, K.L.: "Thymidine Kinase 1 :A Universal Marker for Cancer", CANCER AND CLINICAL ONCOLOGY, vol. 2, no. 1, 2013, pages 159 - 167 |
ANDERSON, C. F.; MOSSER, D. M.: "A novel phenotype for an activated macrophage: the type 2 activated macrophage", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 72, no. 1, 2002, pages 101 - 6, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/12101268> |
ANDERSON, C. F.; MOSSER, D. M: "A novel phenotype for an activated macrophage: the type 2 activated macrophage", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 72, no. 1, 2002, pages 101 - 6, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/12101268> |
ANDREESEN, R.; SCHEIBENBOGEN, C.; BRUGGER, W., CANCER RESEARCH, vol. ADOPTIVE, 1990, pages 7450 - 7456, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/50/23/7450.short> |
ANDREESEN, R.; SCHEIBENBOGEN, C.; BRUGGER, W.: "Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy", CANCER RESEARCH, 1990, pages 7450 - 7456, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/50/23/7450.short> |
APOSTOLAKI, M.; ARMAKA, M.; VICTORATOS, P.; KOLLIAS, G.: "Cellular Mechanisms of TNF Function in Models of Inflammation and Autoimmunity", 2010, KARGER PUBLISHERS |
APOSTOLAKI, M.; ARMAKA, M.; VICTORATOS, P.; KOLLIAS, G.: "Mechanisms of TNF Function in Models of Inflammation and Autoimmunity", 2010, KARGER PUBLISHERS |
ARRANZ, A.; DOXAKI, C.; VERGADI, E.; MARTINEZ DE LA TORRE, Y.; VAPORIDI, K.; LAGOUDAKI, E. D.; TSATSANIS, C.: "Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 109, no. 24, 2012, pages 9517 - 22, Retrieved from the Internet <URL:http://doi.org/10.1073/pnas. 1119038109> |
ARRANZ, A.; DOXAKI, C.; VERGADI, E.; MARTINEZ DE LA TORRE, Y.; VAPORIDI, K; LAGOUDAKI, E. D.; TSATSANIS, C.: "Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 109, no. 24, 2012, pages 9517 - 22, Retrieved from the Internet <URL:http://doi.org/10.1073/pnas. 1119038109> |
BACCALA, R.; HOEBE, K.; KONO, D. H.; BEUTLER, B.; THEOFILOPOULOS, A. N.: "TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity", NATURE MEDICINE, vol. 13, no. 5, 2007, pages 543 - 51, Retrieved from the Internet <URL:http://doi.org/1 0.1038/nm 1590> |
BACCALA, R.; HOEBE, K; KONO, D. H.; BEUTLER, B.; THEOFILOPOULOS, A. N.: "TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity", NATURE MEDICINE, vol. 13, no. 5, 2007, pages 543 - 51, Retrieved from the Internet <URL:http://doi.org/10.1038/nm 1590> |
BANERJEE, S.; XIE, N.; CUI, H.; TAN, Z.; YANG, S.; ICYUZ, M.; LIU, G.: "MicroRNA let-7c regulates macrophage polarization", JOURNAL OF IMMUNOLOGY, vol. 190, no. 12, 2013, pages 6542 - 9, Retrieved from the Internet <URL:http://doi.org/10.4049/jimmunol.1202496> |
BANERJEE, S.; XIE, N.; CUI, H.; TAN, Z.; YANG, S.; ICYUZ, M.; LIU, G.: "MicroRNA let-7c regulates macrophage polarization.", JOURNAL OF IMMUNOLOGY, vol. 190, no. 12, 2013, pages 6542 - 9, Retrieved from the Internet <URL:http://doi.org/10.4049/jimmunol.1202496> |
BARROS, M. H. M.; HAUCK, F.; DREYER, J. H.; KEMPKES, B.; NIEDOBITEK, G.: "Macrophage Polarisation: an Immunohistochemical Approach for Identifying M1 and M2 Macrophages", PLOS ONE, vol. 8, no. 11, 2013, pages E80908, Retrieved from the Internet <URL:http://doi.org/10.1371/journal.pone.0080908> |
BETTENCOURT-DIAS, M.; GIET, R.; SINKA, R.; MAZUMDAR, A; LOCK, W. G.; BALLOUX, F.; GLOVER, D. M.: "Genome-wide survey of protein kinases required for cell cycle progression", NATURE, vol. 432, no. 7020, 2004, pages 980 - 7, Retrieved from the Internet <URL:http://doi.org/10.1038/nature03160> |
BETTENCOURT-DIAS, M; GIET, R.; SINKA, R.; MAZUMDAR, A; LOCK, W. G.; BALLOUX, F.; GLOVER, D. M: "Genome-wide survey of protein kinases required for cell cycle progression", NATURE, vol. 432, no. 7020, 2004, pages 980 - 7 |
BINGLE, L.; BROWN, N. J.; LEWIS, C. E.: "The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies", THE JOURNAL OF PATHOLOGY, vol. 196, no. 3, 2002, pages 254 - 65, Retrieved from the Internet <URL:http://doi.org/10.1002/path. 1027> |
BINGLE, L.; BROWN, N. J.; LEWIS, C. E.: "The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies", THE JOURNAL OF PATHOLOGY, vol. 196, no. 3, 2002, pages 254 - 65, Retrieved from the Internet <URL:http://doi.orq/10.1002/path.1027> |
BISWAS, S. K.; GANGI, L.; PAUL, S.; SCHIOPPA, T.; SACCANI, A.; SIRONI, M.; SICA, A.: "A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation", BLOOD, vol. 107, no. 5, 2006, pages 2112 - 22, Retrieved from the Internet <URL:http://doi.org/10.1182/b!ood-2005-01 -0428> |
BISWAS, S. K.; GANGI, L.; PAUL, S.; SCHIOPPA, T.; SACCANI, A.; SIRONI, M.; SICA, A: "A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation", BLOOD, vol. 107, no. 5, 2006, pages 2112 - 22, Retrieved from the Internet <URL:http://doi.org/10.1182/blood-2005-01-0428> |
BLAGIH, J.; JONES, R. G.: "Polarizing macrophages through reprogramming of glucose metabolism", CELL METABOLISM, vol. 15, no. 6, 2012, pages 793 - 5, XP028520514, Retrieved from the Internet <URL:http://doi.org/10.1016/j.cmet.2012.05.008> DOI: doi:10.1016/j.cmet.2012.05.008 |
BLAGIH, J.; JONES, R. G: "Polarizing macrophages through reprogramming of glucose metabolism", CELL METABOLISM, vol. 15, no. 6, 2012, pages 793 - 5, XP028520514, Retrieved from the Internet <URL:http://doi. rg/10.1016/j.cmet.2012.05.008> DOI: doi:10.1016/j.cmet.2012.05.008 |
CAI, X.; YIN, Y.; LI, N.; ZHU, D.; ZHANG, J.; ZHANG, C.-Y.; ZEN, K.: "Re-polarization of tumor-associated macrophages to pro-inflammatory M1 macrophages by microRNA-155", JOURNAL OF MOLECULAR CELL BIOLOGY, vol. 4, no. 5, 2012, pages 341 - 3, Retrieved from the Internet <URL:http://doi.org/10.1093/jmcb/mjs044> |
CAI, X.; YIN, Y.; LI, N.; ZHU, D.; ZHANG, J.; ZHANG, C.-Y.; ZEN, K: "Re-polarization of tumor-associated macrophages to pro-inflammatory M1 macrophages by microRNA-155", JOURNAL OF MOLECULAR CELL BIOLOGY, vol. 4, no. 5, 2012, pages 341 - 3, Retrieved from the Internet <URL:http:/.Idoi.org/10.1093/jmcb/r-mjs044> |
CANCER FACTS & FIGURES, 2015 |
CANCER FACTS AND FIGURES, 2015 |
CHEN, H.; LI, P.; YIN, Y.; CAI, X.; HUANG, Z.; CHEN, J.; ZHANG, J.: "The promotion of type 1 T helper cell responses to cationic polymers in vivo via toll-like receptor-4 mediated IL-12 secretion", BIOMATERIALS, vol. 31, no. 32, 2010, pages 8172 - 80, XP027259521, Retrieved from the Internet <URL:http://doi.org/10.1016/j.biomateria!s.2010.07.056> |
CHEN, H.; LI, P.; YIN, Y.; CAI, X.; HUANG, Z.; CHEN, J.; ZHANG, J.: "The promotion of type 1 T helper cell responses to cationic polymers in vivo via toll-like receptor-4 mediated IL-12 secretion", BIOMATERIALS, vol. 31, no. 32, 2010, pages 8172 - 80, XP027259521, Retrieved from the Internet <URL:http://doi.org/10.1016/j.biomaterials.2010.07.056> |
CORTEZ-RETAMOZO, V.; ETZRODT, M.; NEWTON, A.; RAUCH, P. J.; CHUDNOVSKIY, A.; BERGER, C.; PITTET, M. J.: "Origins of tumor-associated macrophages and neutrophils", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 109, no. 7, 2012, pages 2491 - 6, Retrieved from the Internet <URL:http://doi.org/10.1073/pnas. 1113744109> |
CORTEZ-RETAMOZO, V.; ETZRODT, M.; NEWTON, A.; RAUCH, P. J.; CHUDNOVSKIY, A.; BERGER, C.; PITTET, M. J.: "Origins of tumor-associated macrophages and neutrophils", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 109, no. 7, 2012, pages 2491 - 6, Retrieved from the Internet <URL:http://doi.org/10.1073/pnas.1113744109> |
DALTON, H. J.; ARMAIZ-PENA, G. N.; GONZALEZ-VILLASANA, V.; LOPEZ-BERESTEIN, G.; BAR-ELI, M.; SOOD, A. K.: "Monocyte subpopulations in angiogenesis", CANCER RESEARCH, vol. 74, no. 5, 2014, pages 1287 - 93, Retrieved from the Internet <URL:http://doi.org/10.1158/0008-5472.CAN-13-2825> |
DAVIS, M. J.; TSANG, T. M.; QIU, Y.; DAYRIT, J. K.; FREIJ, J. B.; HUFFNAGLE, G. B.; OLSZEWSKI, M. A.: "Macrophage M1/M2 polarization dynamically adapts to changes in cytokine microenvironments in Cryptococcus neoformans infection", MBIO, no. 3, 2013, pages E00264 - 13, Retrieved from the Internet <URL:http://doi.org/10.1128/mBio.00264-13> |
DAVIS, M. J.; TSANG, T. M.; QIU, Y.; DAYRIT, J. K; FREIJ, J. B.; HUFFNAGLE, G. B.; OLSZEWSKI, M. A: "Macrophage M1/M2 polarization dynamically adapts to changes in cytokine microenvironments in Cryptococcus neoformans infection", MBIO, vol. 4, no. 3, 2013, pages E00264 - 13, Retrieved from the Internet <URL:http://doi.org/10.1128/mBio.00264-13> |
EDIN, S.; WIKBERG, M. L.; DAHLIN, A. M.; RUTEGARD, J.; OBERG, A.; OLDENBORG, P.-A.; PALMQVIST, R.: "The distribution of macrophages with a m1 or m2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer", PLOS ONE, vol. 7, no. 10, 2012, pages E47045, Retrieved from the Internet <URL:http://doi.org/10.1371/journal.pone.0047045> |
EIRO, N.; VIZOSO, F. J.: "Inflammation and cancer", WORLD JOURNAL OF GASTROINTESTINAL SURGERY, vol. 4, no. 3, 2012, pages 62 - 72, XP055469172, Retrieved from the Internet <URL:http://doi.org/10.4240/wjgs.v4.i3.62> DOI: doi:10.4240/wjgs.v4.i3.62 |
EIRÓ, N.; VIZOSO, F. J: "Inflammation and cancer", WORLD JOURNAL OF GASTROINTESTINAL SURGERY, vol. 4, no. 3, 2012, pages 62 - 72, XP055469172, Retrieved from the Internet <URL:http://doi.org/10.4240/wigs.v4.i3.62> DOI: doi:10.4240/wjgs.v4.i3.62 |
ELLEM, K. A. 0.; ROURKE, M. G. E. 0.; JOHNSON, G. R.; PARRY, G.; MISKO, I. S.; SCHMIDT, C. W.; MULLIGAN, R. C: "A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma", CANCER IMMUNOLOGY, IMMUNOTHERAPY, 1997, pages 10 - 20, XP035544823, Retrieved from the Internet <URL:http://www.springerlink.com/index/JQ4EB21 E4C7ADMT7.pd> DOI: doi:10.1007/s002620050349 |
ELLEM, K. A. O.; ROURKE, M. G. E. O.; JOHNSON, G. R.; PARRY, G.; MISKO, I. S.; SCHMIDT, C. W.; MULLIGAN, R. C.: "A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma", CANCER IMMUNOLOGY, IMMUNOTHERAPY, 1997, pages 10 - 20, XP035544823, Retrieved from the Internet <URL:http://www.springerlink.com/index/JQ4EB21 E4C7ADMT7.pdf> DOI: doi:10.1007/s002620050349 |
FORSSELL, J.; OBERG, A.; HENRIKSSON, M. L.; STENLING, R.; JUNG, A.; PALMQVIST, R.: "High macrophage infiltration along the tumor front correlates with improved survival in colon cancer", CLINICAL CANCER RESEARCH, vol. 13, no. 5, 2007, pages 1472 - 9, XP055107292, Retrieved from the Internet <URL:http://doi.org/10.1158/1078-0432.CCR-06-2073> DOI: doi:10.1158/1078-0432.CCR-06-2073 |
GARRIDO F; CABRERA T; CONCHA A; GLEW S; RUIZ-CABELLO F; STERN PL: "Natural history of HLA expression during tumour development", IMMUNOL TODAY, vol. 14, pages 491 9, Retrieved from the Internet <URL:http://dx.doi.org/10.1016/0167-5699(93)90264-L> |
GAST, G. DE; KLUMPEN, H.: "immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon α in progressive metastatic melanoma", CLINICAL CANCER RESEARCH, 2000, Retrieved from the Internet <URL:http://clincancerres. aacrjournals. org/content/6/4/1267. short> |
GAST, G. DE; KLUMPEN, H: "immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon α in progressive metastatic melanoma", CLINICAL CANCER RESEARCH, 2000, Retrieved from the Internet <URL:http://clincancerres.aacrjournals.org/content/6/4/1267.short> |
GAZZANIGA, S.; BRAVO, A. I.; GUGLIELMOTTI, A.; VAN ROOIJEN, N.; MASCHI, F.; VECCHI, A.; WAINSTOK, R.: "argeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 127, no. 8, 2007, pages 2031 - 41, XP055124836, Retrieved from the Internet <URL:http://doi.org/10.1038/sj.jid.5700827> DOI: doi:10.1038/sj.jid.5700827 |
GAZZANIGA, S.; BRAVO, A. I; GUGLIELMOTTI, A.; VAN ROOIJEN, N.; MASCHI, F.; VECCHI, A.; WAINSTOK, R.: "Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft.", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 127, no. 8, 2007, pages 2031 - 41, XP055124836, Retrieved from the Internet <URL:http://doi.org/10.1038/sj.jid.5700827> DOI: doi:10.1038/sj.jid.5700827 |
GESCHWIND, J. H.; VALI, M.; WAHL, R.: "Effects of 3 -bromopyruvate (hexokinase 2 inhibitor) on glucose uptake in lewis rats using 2-(F-18) fluoro-2-deoxy-d-glucose", GASTROINTESTINAL CANCERS SYMPOSIUM, 2006, pages 12 - 14 |
GESCHWIND, J. H.; VALI, M.; WAHL, R.: "Effects of 3 bromopyruvate (hexokinase 2 inhibitor) on glucose uptake in lewis rats using 2-(F-18) fluoro-2-deoxy-d-glucose", GASTROINTESTINAL CANCERS SYMPOSIUM, 2006, pages 12 - 14 |
GHASSABEH, G. H.; DE BAETSELIER, P.; BRYS, L.; NOEL, W.; VAN GINDERACHTER; J. A, MEERSCHAUT, S.; RAES, G.: "Identification of a common gene signature for type II cytokine-associated myeloid cells elicited in vivo in different pathologic conditions", BLOOD, vol. 108, no. 2, 2006, pages 575 - 83, XP002402878, Retrieved from the Internet <URL:http://doi.org/10.1182/blood-2005-04-1485> DOI: doi:10.1182/blood-2005-04-1485 |
GOLDENBERG MM: "Trastuzumab, a recombinant DNA derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer", CLIN THER, vol. 21, 1999, pages 309 - 18, XP000918210, Retrieved from the Internet <URL:http://dx.doi. org/10.1016/S0149-2918(00)88288-0> DOI: doi:10.1016/S0149-2918(00)88288-0 |
GRILLO-L.PEZ AJ; WHITE CA; VARNS C; SHEN D; WEI A; MCCLURE A ET AL.: "Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma", SEMIN ONCOL, vol. 26, 1999, pages 66 - 73, XP009036169 |
GUIDUCCI, C.; VICARI, A. P.; SANGALETTI, S.; TRINCHIERI, G.; COLOMBO, M. P.: "Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection", CANCER RESEARCH, vol. 65, no. 8, 2005, pages 3437 - 46, XP009510468, Retrieved from the Internet <URL:http://doi.org/10.1158/0008-5472.CAN-04-4262> DOI: doi:10.1158/0008-5472.CAN-04-4262 |
GUIDUCCI, C.; VICARI, A. P.; SANGALETTI, S.; TRINCHIERI, G.; COLOMBO, M. P: "Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection", CANCER RESEARCH, vol. 65, no. 8, 2005, pages 3437 - 46, XP009510468, Retrieved from the Internet <URL:http://doi.org/10.1158/0008-5472.CAN-04-4262> DOI: doi:10.1158/0008-5472.CAN-04-4262 |
HAGEMANN, T.; LAWRENCE, T.; MCNEISH, I.; CHARLES, K. A; KULBE, H.; THOMPSON, R. G.; BALKWILL, F. R.: "Re-educating'' tumor-associated macrophages by targeting NF-kappaB", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 205, no. 6, 2008, pages 1261 - 8, Retrieved from the Internet <URL:http://doi.org/10.1084/jem.20080108> |
HAGEMANN, T.; WILSON, J.; BURKE, F.; KULBE, H.; LI, N. F.; PLUDDEMANN, A.; BALKWILL, F. R.: "Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype", THE JOURNAL OF IMMUNOLOGY, vol. 176, no. 8, 2006, pages 5023 - 32, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/16585599> |
HAGEMANN, T.; WILSON, J.; BURKE, F.; KULBE, H.; LI, N. F.; PLUDDEMANN, A.; BALKWILL, F. R: "Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype", THE JOURNAL OF IMMUNOLOGY, vol. 176, no. 8, 2006, pages 5023 - 32, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/16585599> |
HANAHAN, D.; WEINBERG, R. A.: "Hallmarks of cancer: the next generation", CELL, vol. 144, no. 5, 2011, pages 646 - 74, XP028185429, Retrieved from the Internet <URL:ttp://doi.org/10.1016/j.cell.2011.02.013> DOI: doi:10.1016/j.cell.2011.02.013 |
HANAHAN, D.; WEINBERG, R. A: "Hallmarks of cancer: the next generation", CELL, vol. 144, no. 5, 2011, pages 646 - 74, XP028185429, Retrieved from the Internet <URL:http://doi.org/10.1016/j.ce!!.2011.02.013> DOI: doi:10.1016/j.cell.2011.02.013 |
HAO, N.-B.; LU, M.-H.; FAN, Y.-H.; CAO, Y.-L.; ZHANG, Z.-R.; YANG, S.-M: "Macrophages in tumor microenvironments and the progression of tumors", CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2012, pages 948098, Retrieved from the Internet <URL:http://doi.org/10.1155/2012/948098> |
HAO, N.-B.; LU, M.-H.; FAN, Y.-H.; CAO, Y.-L.; ZHANG, Z.-R.; YANG, S.-M: "Macrophages in tumor microenvironments and the progression of tumors", CLINICAL & DEVELOPMENTAL IMMUNOLOGY,, 2012, pages 948098, Retrieved from the Internet <URL:http://doi.org/10.1155/2012/948098> |
HARDISON, S. E.; HERRERA, G.; YOUNG, M. L.; HOLE, C. R.; WOZNIAK, K. L.; WORMLEY, F. L.: "Protective immunity against pulmonary cryptococcosis is associated with STAT1-mediated classical macrophage activation", JOURNAL OF IMMUNOLOGY, vol. 189, no. 8, 2012, pages 4060 - 8, Retrieved from the Internet <URL:http://doi.org/10.4049/jimmunoi.1103455> |
HARDISON, S. E; HERRERA, G.; YOUNG, M. L.; HOLE, C. R.; WOZNIAK, K. L.; WORMLEY, F. L.: "Protective immunity against pulmonary cryptococcosis is associated with STAT1-mediated classical macrophage activation", JOURNAL OF IMMUNOLOGY, vol. 189, no. 8, 2012, pages 4060 - 8 |
HASCHEMI, A.; KOSMA, P.; GILLE, L.; EVANS, C. R.; BURANT, C. F.; STARKL, P.; WAGNER, O.: "The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism", CELL METABOLISM, vol. 15, no. 6, 2012, pages 813 - 26, XP028520508, Retrieved from the Internet <URL:http://doi. rg/10.1016/j.cmet.2012.04.023> DOI: doi:10.1016/j.cmet.2012.04.023 |
HASCHEMI, A.; KOSMA, P; GILLE, L.; EVANS, C. R.; BURANT, C. F.; STARKL, P.; WAGNER, O: "The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism", CELL METABOLISM, vol. 15, no. 6, 2012, pages 813 - 26, XP028520508, Retrieved from the Internet <URL:http://doi.org/10.1016/j.cmet.2012.04.023> DOI: doi:10.1016/j.cmet.2012.04.023 |
HASSABEH, G. H.; DE BAETSELIER, P.; BRYS, L.; NOEL, W.; VAN GINDERACHTER; MEERSCHAUT, S.; RAES, G: "Identification of a common gene signature for type II cytokine-associated myeloid cells elicited in vivo in different pathologic conditions", BLOOD, vol. 108, no. 2, 2006, pages 575 - 83, XP002402878, Retrieved from the Internet <URL:http://doi.org/10.1182/blood-2005-04-1485> DOI: doi:10.1182/blood-2005-04-1485 |
HERBEUVAL, J.-P.; LAMBERT, C.; SABIDO, 0.; COTTIER, M.; FOURNEL, P.; DY, M; GENIN, C: "Macrophages from cancer patients: analysis of TRAIL, TRAIL receptors, and colon tumor cell apoptosis", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 95, no. 8, 2003, pages 611 - 21, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/12697854> |
HERBEUVAL, J.-P.; LAMBERT, C.; SABIDO, O.; COTTIER, M.; FOURNEL, P.; DY, M.; GENIN, C.: "Macrophages from cancer patients: analysis of TRAIL, TRAIL receptors, and colon tumor", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 95, no. 8, 2003, pages 611 - 21, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/12697854> |
HERCUS, T. R.; THOMAS, D.; GUTHRIDGE, M. A.; EKERT, P. G.; KING-SCOTT, J.; PARKER, M. W.; LOPEZ, A. F: "The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease", BLOOD, vol. 114, no. 7, 2009, pages 1289 - 98, Retrieved from the Internet <URL:http://doi.org/10.1182/blood-2008-12-164004> |
HERCUS, T. R; THOMAS, D.; GUTHRIDGE, M. A.; EKERT, P. G.; KING-SCOTT, J.; PARKER, M. W.; LOPEZ, A. F.: "The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease", BLOOD, vol. 114, no. 7, 2009, pages 1289 - 98, Retrieved from the Internet <URL:http://doi.org/10.1182/blood-2008-12-164004> |
HILL, H., JR, T. C.; SABEL, M.: "Immunotherapy with Interleukin 12 and Granulocyte-Macrophage Colony-stimulating Factor-encapsulated Microspheres Coinduction of Innate and Adaptive Antitumor", CANCER RESEARCH, 2002, Retrieved from the Internet <URL:http://cancerres. aacrjournals. org/content/62/24/7254. short> |
HILL, H., JR, T. C.; SABEL, M.: "Immunotherapy with Interleukin 12 and Granulocyte-Macrophage Colony-stimulating Factor-encapsulated Microspheres Coinduction of Innate and Adaptive Antitumor", CANCER RESEARCH, 2002, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/62/24/7254.short> |
HOYERT, D. L.; XU, J., NATIONAL VITAL STATISTICS REPORTS DEATHS: PRELIMINARY DATA FOR 2011, vol. 61, 2012 |
HU, Y; ZHANG, H.; LU, Y; BAI, H.; XU, Y.; ZHU, X.; CHEN, Q.: "Class A scavenger receptor attenuates myocardial infarction-induced cardiomyocyte necrosis through suppressing M1 macrophage subset polarization", BASIC RESEARCH IN CARDIOLOGY, vol. 106, no. 6, 2011, pages 1311 - 28, Retrieved from the Internet <URL:http://doi.org/10.1007/s00395-011 -0204-x> |
HUANG, Z.; YANG, Y.; JIANG, Y.; SHAO, J.; SUN, X.; CHEN, J.; ZHANG, J.: "Anti-tumor immune responses of tumor-associated macrophages via toll-like receptor 4 triggered by cationic polymers", BIOMATERIALS, vol. 34, no. 3, 2013, pages 746 - 55, XP055333314, Retrieved from the Internet <URL:http://doi.org/10.1016/j.biomateria!s.2012.09.062> DOI: doi:10.1016/j.biomaterials.2012.09.062 |
HUANG, Z.; YANG, Y.; JIANG, Y.; SHAO, J.; SUN, X.; CHEN, J.; ZHANG, J.: "Anti-tumor immune responses of tumor-associated macrophages via toll-like receptor 4 triggered by cationic polymers", BIOMATERIALS, vol. 34, no. 3, 2013, pages 746 - 55, XP055333314, Retrieved from the Internet <URL:http://doi.org/10.1016/j.biomaterials.2012.09.062> DOI: doi:10.1016/j.biomaterials.2012.09.062 |
JAFFEE, E.; HRUBAN, R.: "Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation", JOURNAL OF CLINICAL ., vol. 19, no. 1, 2001, pages 145 - 156, XP007900372 |
JI, Y.; SUN, S.; XU, A.; BHARGAVA, P.; YANG, L.; LAM, K. S. L.; QI, L.: "Activation of natural killer T cells promotes M2 Macrophage polarization in adipose tissue and improves systemic glucose tolerance via interleukin-4 (IL-4)/STAT6 protein signaling axis in obesity", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 287, no. 17, 2012, pages 13561 - 71, Retrieved from the Internet <URL:http://doi.org/10.1074/jbc.M112.350066> |
JI, Y.; SUN, S.; XU, A.; BHARGAVA, P.; YANG, L; LAM, K. S. L.; QI, L.: "Activation of natural killer T cells promotes M2 Macrophage polarization in adipose tissue and improves systemic glucose tolerance via interleukin-4 (IL-4)/STAT6 protein signaling axis in obesity", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 287, no. 17, 2012, pages 13561 - 71, Retrieved from the Internet <URL:http://doi.org/10.1074/jbc.M112.350066> |
JOHNS, T.; MACKAY, I: "Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon Î2", JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, pages 1185 - 1190, Retrieved from the Internet <URL:http://jnci.oxfordjournals.org/content/84/15/1185> |
JONES, R. G.; THOMPSON, C. B.: "Revving the engine: signal transduction fuels T cell activation", IMMUNITY, vol. 27, no. 2, 2007, pages 173 - 8, Retrieved from the Internet <URL:http://doi.org/10.1016/j.immuni.2007.07.008> |
JUNANKAR, S.; SHAY, G.; JURCZYLUK, J.; ALI, N.; DOWN, J.; POCOCK, N.; ROGERS, M. J.: "Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer", CANCER DISCOVERY, vol. 5, no. 1, 2015, pages 35 - 42, Retrieved from the Internet <URL:http://doi.org/10.1158/2159-8290.CD-14-0621> |
JUNANKAR, S.; SHAY, G.; JURCZYLUK, J.; ALI, N.; DOWN, J.; POCOCK, N; ROGERS, M. J.: "Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer", CANCER DISCOVERY, vol. 5, no. 1, 2015, pages 35 - 42, Retrieved from the Internet <URL:http://doi.org/10.1158/2159-8290.CD-14-0621> |
K. L. O'NEILL; M. HOPER; G. W. ODLING-SMEE: "Can thymidine kinase levels in breast tumors predict disease recurrence?", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 84, no. 23, 1992, pages 1825 - 1828 |
KARYAMPUDI L; KNUTSON KL: "Antibodies in cancer immunotherapy", CANCER BIOMARK, vol. 6, 2010, pages 291 - 305 |
KELLY, P. M.; DAVISON, R. S.; BLISS, E.; MCGEE, J. O.: "Macrophages in human breast disease: a quantitative immunohistochemical study", BRITISH JOURNAL OF CANCER, vol. 57, no. 2, 1988, pages 174 - 7, Retrieved from the Internet <URL:http://www.pubmedcentral. nih.gov/articlerender. fcgi?artid=2246436&tool= pmcentrez&rendertype=abstract> |
KELLY, P. M.; DAVISON, R. S.; BLISS, E.; MCGEE, J. O: "Macrophages in human breast disease: a quantitative immunohistochemical study", BRITISH JOURNAL OF CANCER, vol. 57, no. 2, 1988, pages 174 - 7, Retrieved from the Internet <URL:http://www.pubmedcentral. nih.gov/articlerender. fcgi?artid=2246436 &tool=pmcentrez&rendertype=abstract> |
KIMURA, Y. N.; WATARI, K.; FOTOVATI, A.; HOSOI, F.; YASUMOTO, K.; IZUMI, H.; ONO, M.: "Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis", CANCER SCIENCE, vol. 98, no. 12, 2007, pages 2009 - 18, Retrieved from the Internet <URL:http://doi.org/10.1111/j.1349-7006.2007.00633.x> |
KIMURA, Y. N; WATARI, K.; FOTOVATI, A.; HOSOI, F.; YASUMOTO, K.; IZUMI, H.; ONO, M.: "Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis", CANCER SCIENCE, vol. 98, no. 12, 2007, pages 2009 - 18, Retrieved from the Internet <URL:http://doi.org/10.1111/j.1349-7006.2007.00633.x> |
KOLB, W.; GRANGER, G.: "Lymphocyte in vitro cytotoxicity: characterization of human lymphotoxin", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1968, pages 1250 - 1255, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC225248> |
KOLB, W.; GRANGER, G: "Lymphocyte in vitro cytotoxicity: characterization of human lymphotoxin", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1968, pages 1250 - 1255, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC225248> |
KORBELIK, M.; NARAPARAJU, V. R.; YAMAMOTO, N.: "Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer", BRITISH JOURNAL OF CANCER, vol. 75, no. 2, 1997, pages 202 - 7, XP009061849, Retrieved from the Internet <URL:http-//www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2063270 &tool=pmcentrez&rendertype=abstract> |
KORBELIK, M.; NARAPARAJU, V. R.; YAMAMOTO, N.: "Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer", BRITISH JOURNAL OF CANCER, vol. 75, no. 2, 1997, pages 202 - 7, XP009061849, Retrieved from the Internet <URL:http://www.pubmedcentral. nih.gov/articlerender. fcgi?artid=2063270&tool= pmcentrez&rendertype=abstract> |
KUNIK V; ASHKENAZI S; OFRAN Y: "Paratome: An online tool for systematic identification of antigen binding regions in antibodies based on sequence or structure", NUCLEIC ACIDS RES., vol. 40, 6 June 2012 (2012-06-06), pages W521 - 4, XP055246927, DOI: doi:10.1093/nar/gks480 |
KURAHARA, H.; SHINCHI, H.; MATAKI, Y.; MAEMURA, K.; NOMA, H.; KUBO, F.; TAKAO, S: "Significance of M2-polarized tumor-associated macrophage in pancreatic cancer", THE JOURNAL OF SURGICAL RESEARCH, vol. 167, no. 2, 2011, pages E211 - 9, Retrieved from the Internet <URL:http://doi.org/10.1016/jjss.2009.05.026> |
KURAHARA, H; SHINCHI, H.; MATAKI, Y.; MAEMURA, K.; NOMA, H.; KUBO, F.; TAKAO, S.: "Significance of M2-polarized tumor-associated macrophage in pancreatic cancer", THE JOURNAL OF SURGICAL RESEARCH, vol. 167, no. 2, 2011, pages E211 - 9, Retrieved from the Internet <URL:http://doi.org/10.1016/j.jss.2009.05.026> |
LAWRENCE, T.; NATOLI, G.: "Transcriptional regulation of macrophage polarization: enabling diversity with identity", NATURE REVIEWS. IMMUNOLOGY, vol. 11, no. 11, 2011, pages 750 - 61, XP009160964, Retrieved from the Internet <URL:http://doi.org/10.1038/nri3088> DOI: doi:10.1038/nri3088 |
LEWIS, C.; LEEK, R.: "Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages", JOURNAL OF LEUKOCYTE ., vol. 57, May 1995 (1995-05-01), pages 747 - 751, Retrieved from the Internet <URL:http://www.jieukbio.org/content/57/5/747.short> |
LEWIS, C.; LEEK, R: "Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages", JOURNAL OF LEUKOCYTE, vol. 57, May 1995 (1995-05-01), pages 747 - 751, Retrieved from the Internet <URL:http://www.jleukbio.orgilcontent/57115/747. short> |
LIAO, X.; SHARMA, N.; KAPADIA, F.: "Kruppel-like factor 4 regulates macrophage polarization", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 121, no. 7, 2011, Retrieved from the Internet <URL:http://doi.org/10.1172/JC145444DS1> |
LIAO, X.; SHARMA, N.; KAPADIA, F.: "Kruppel-like factor 4 regulates macrophage polarization", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 121, no. 7, 2011, Retrieved from the Internet <URL:http://doi.org/10.1172/JCI45444DS 1> |
LIN, E. Y.; LI, J.-F.; GNATOVSKIY, L.; DENG, Y.; ZHU, L.; GRZESIK, D. A; POLLARD, J. W.: "Macrophages regulate the angiogenic switch in a mouse model of breast cancer", CANCER RESEARCH, vol. 66, no. 23, 2006, pages 11238 - 46, Retrieved from the Internet <URL:http://doi.org/10.1158/0008-5472.CAN-06-1278> |
LIN, E. Y.; LI, J.-F.; GNATOVSKIY, L.; DENG, Y.; ZHU, L.; GRZESIK, D; POLLARD, J. W.: "Macrophages regulate the angiogenic switch in a mouse model of breast cancer", CANCER RESEARCH, vol. 66, no. 23, 2006, pages 11238 - 46, Retrieved from the Internet <URL:http://doi.org/10.1158/0008-5472.CAN-06-1278> |
LIN, E. Y.; POLLARD, J. W: "Tumor-associated macrophages press the angiogenic switch in breast cancer", CANCER RESEARCH, vol. 67, no. 11, 2007, pages 5064 - 6, Retrieved from the Internet <URL:http://doi.org/10.1158/0008-5472.CAN-07-0912> |
LODISH, H. F.; ZHOU, B.; LIU, G.; CHEN, C.-Z.: "Micromanagement of the immune system by microRNAs", NATURE REVIEWS. IMMUNOLOGY, vol. 8, no. 2, 2008, pages 120 - 30, XP002681811, Retrieved from the Internet <URL:http://doi.org/10.1038/nri2252> DOI: doi:10.1038/NRI2252 |
LOKSHIN, A.; MAYOTTE, J.; LEVITT, M.: "Mechanism of Interferon Beta-Induced Squamous Differentiation and Programmed Cell Death in Human Non-Small-Cell Lung Cancer Cell Lines", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 87, 1995, pages 206 - 212, Retrieved from the Internet <URL:http://jnci.oxfordiournais.org/content/87/3/206.short> |
LOKSHIN, A; MAYOTTE, J.; LEVITT, M.: "Mechanism of Interferon Beta-Induced Squamous Differentiation and Programmed Cell Death in Human Non-Small-Cell Lung Cancer Cell Lines", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 87, 1995, pages 206 - 212, Retrieved from the Internet <URL:http://j nci. oxfordjournals. org/content/87 /3/206. short> |
LUO, Y.; ZHOU, H.; KRUEGER, J: "Targeting tumor-associated macrophages as a novel strategy against breast cancer", JOURNAL OF CLINICAL INVESTIGATION, vol. 116, no. 8, 2006, pages 2132 - 2141, Retrieved from the Internet <URL:httg://doi.org/10.1172/JCl27648.2132> |
LUO, Y.; ZHOU, H; KRUEGER, J: "Targeting tumor-associated macrophages as a novel strategy against breast cancer", JOURNAL OF CLINICAL INVESTIGATION, vol. 116, no. 8, 2006, pages 2132 - 2141, Retrieved from the Internet <URL:http://doi.org/10.1172/JCI27648.2132> |
MA, J.; LIU, L.; CHE, G.; YU, N.; DAI, F.; YOU, Z.: "The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time", BMC CANCER, vol. 10, 2010, pages 112, XP021074951, Retrieved from the Internet <URL:http://doi.org/10.1186/1471 -2407-10-112> DOI: doi:10.1186/1471-2407-10-112 |
MA, J.; LIU, L.; CHE, G; YU, N.; DAI, F.; YOU, Z: "The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time", BMC CANCER, vol. 10, 2010, pages 112, XP021074951, Retrieved from the Internet <URL:http://doi.org/10.1186/1471-2407-10-112> DOI: doi:10.1186/1471-2407-10-112 |
MANDAL, P.; PRATT, B. T.; BARNES, M., MCMULLEN, M. R.; NAGY, L. E.: "Molecular mechanism for adiponectin-dependent M2 macrophage polarization: link between the metabolic and innate immune activity of full-length adiponectin", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 15, 2011, pages 13460 - 9, Retrieved from the Internet <URL:http://doi.org/10.1074/jbc.M110.204644> |
MANDAL, P.; PRATT, B. T.; BARNES, M.; MCMULLEN, M. R.; NAGY, L. E.: "Molecular mechanism for adiponectin-dependent M2 macrophage polarization: link between the metabolic and innate immune activity of full-length adiponectin", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 15, 2011, pages 13460 - 9, Retrieved from the Internet <URL:http:/.Idoi.org/10.1074/jbc.M110.204644> |
MANTOVANI, A.; ALLAVENA, P.; SICA, A.; BALKWILL, F.: "Cancer-related inflammation", NATURE, vol. 454, no. 7203, 2008, pages 436 - 44, XP055175816, Retrieved from the Internet <URL:http:Hdoi.org/10.1038/nature07205> DOI: doi:10.1038/nature07205 |
MANTOVANI, A.; ALLAVENA, P; SICA, A; BALKWILL, F.: "Cancer-related inflammation", NATURE, vol. 454, no. 7203, 2008, pages 436 - 44, XP055175816, Retrieved from the Internet <URL:http://doi.org/10.1038/nature07205> DOI: doi:10.1038/nature07205 |
MANTOVANI, A.; BISWAS, S. K.; GALDIERO, M. R.; SICA, A.; LOCATI, M.: "Macrophage plasticity and polarization in tissue repair and remodelling", THE JOURNAL OF PATHOLOGY, vol. 229, no. 2, 2013, pages 176 - 85, Retrieved from the Internet <URL:http://doi.orc /10.1002/path.4133> |
MANTOVANI, A.; BISWAS, S. K.; GALDIERO, M. R.; SICA, A.; LOCATI, M.: "Macrophage plasticity and polarization in tissue repair and remodelling", THE JOURNAL OF PATHOLOGY, vol. 229, no. 2, 2013, pages 176 - 85, Retrieved from the Internet <URL:http://doi.org/10.1002/path.4133> |
MANTOVANI, A.; SOZZANI, S.; LOCATI, M.; ALLAVENA, P.; SICA, A.: "Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes", TRENDS IN IMMUNOLOGY, vol. 23, no. 11, 2002, pages 549 - 55, XP004388301, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/12401408> DOI: doi:10.1016/S1471-4906(02)02302-5 |
MANTOVANI, A.; SOZZANI, S.; LOCATI, M.; ALLAVENA, P.; SICA, A: "Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes", TRENDS IN IMMUNOLOGY,, vol. 23, no. 11, 2002, pages 549 - 55, XP004388301, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/12401408> DOI: doi:10.1016/S1471-4906(02)02302-5 |
MEIDENBAUER N; ZIPPELIUS A; PITTET MJ; LAUMER M; VOGL S; HEYMANN J ET AL.: "High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma", CANCER RES, vol. 64, 2004, pages 6319 - 26, Retrieved from the Internet <URL:http://dx.doi.org/10.1158/0008-5472. CAN-04-1341> |
MICHEL, 0.; NAGY, A.: "Dose-response relationship to inhaled endotoxin in normal subjects", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 156, no. 4, 1997, pages 1157 - 64, XP055188959, Retrieved from the Internet <URL:http://www.atsjournals.org/d0i/abs/10.1164/ajrccm.156.4.97-02002> DOI: doi:10.1164/ajrccm.156.4.97-02002 |
MICHEL, 0; NAGY, A.: "Dose-response relationship to inhaled endotoxin in normal subjects", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 156, no. 4, 1997, pages 1157 - 64, XP055188959, Retrieved from the Internet <URL:http://www.atsjournals.org/doi/abs/10.1164/ajrccm.156.4.97-02002> DOI: doi:10.1164/ajrccm.156.4.97-02002 |
MILLS, C. D.; SHEARER, J.; EVANS, R.; CALDWELL, M. D: "Macrophage arginine metabolism and the inhibition or stimulation of cancer", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950, vol. 149, no. 8, 1992, pages 2709 - 14, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/1401910> |
MILLS, C. D.; SHEARER, J.; EVANS, R; CALDWELL, M. D.: "Macrophage arginine metabolism and the inhibition or stimulation of cancer", JOURNAL OF IMMUNOLOGY, vol. 149, no. 8, 1992, pages 2709 - 14, Retrieved from the Internet <URL:http://www ncbi.nlm nih.gov/pubmed/1401910> |
MURRAY, P. J.; ALLEN, J. E.; BISWAS, S. K.; FISHER, E. A.; GILROY, D. W.; GOERDT, S.; WYNN, T. A.: "Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines", IMMUNITY, vol. 41, no. 1, 2014, pages 14 - 20, XP002776702, Retrieved from the Internet <URL:http://doi.org/10.1016/m.immuni.2014.06.008> DOI: doi:10.1016/j.immuni.2014.06.008 |
MURRAY, P. J.; ALLEN, J. E.; BISWAS, S. K.; FISHER, E. A.; GILROY, D. W.; GOERDT, S.; WYNN, T. A: "Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines", IMMUNITY, vol. 41, no. 1, 2014, pages 14 - 20, XP002776702, Retrieved from the Internet <URL:http://doi.Org/10.1016/j.immuni.2014.06.008> DOI: doi:10.1016/j.immuni.2014.06.008 |
OHRI, C. M.; SHIKOTRA, A.; GREEN, R. H.; WALLER, D. A; BRADDING, P.: "Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival", THE EUROPEAN RESPIRATORY JOURNAL,, vol. 33, no. 1, 2009, pages 118 - 26, Retrieved from the Internet <URL:http:/.Idoi.org/10.1183/09031936,00065708> |
OHRI, C. M.; SHIKOTRA, A.; GREEN, R. H.; WALLER, D. A; BRADDING, P: "Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival", THE EUROPEAN RESPIRATORY JOURNAL, vol. 33, no. 1, 2009, pages 118 - 26, Retrieved from the Internet <URL:http://doi.org/10.1183/09031936.00065708> |
O'NEILL, K. L.; BUCKWALTER, M. R.; MURRAY, B. K.: "Thymidine kinase: diagnostic and prognostic potential", EXPERT REV MOL DIAGN, vol. 1, no. 4, 2001, pages 428 - 433, Retrieved from the Internet <URL:http://dx.doi.org/ 10.1586/14737159.1.4.428> |
PORTA, C.; RIMOLDI, M.; RAES, G., BRYS, L.; GHEZZI, P.; DI LIBERTO, D.; SICA, A: "Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 106, no. 35, 2009, pages 14978 - 83, Retrieved from the Internet <URL:http://doi.org/10.1073/pnas.0809784106> |
PORTA, C.; RIMOLDI, M.; RAES, G.; BRYS, L.; GHEZZI, P.; DI LIBERTO, D.; SICA, A.: "Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 106, no. 35, 2009, pages 14978 - 83, Retrieved from the Internet <URL:http://doi.org/10.1073/pnas.0809784106> |
Q. HE; T. FORNANDER; H. JOHANSSON ET AL.: "Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer", ANTICANCER RESEARCH, vol. 26, no. 6, 2006, pages 4753 - 4759 |
QIN, X.-Q.; RUNKEL, L.; DECK, C.; DEDIOS, C.; BARSOUM, J: "Interferon-beta induces S phase accumulation selectively in human transformed cells", JOURNAL OF INTERFERON & CYTOKINE RESEARCH, vol. 17, no. 6, 1997, pages 355 - 367, XP000886677, Retrieved from the Internet <URL:http://doi.org/10.1089/jir.1997.17.355> |
QIN, X.-Q.; RUNKEL, L.; DECK, C; DEDIOS, C.; BARSOUM, J.: "Interferon-beta induces S phase accumulation selectively in human transformed cells.", JOURNAL OF INTERFERON & CYTOKINE RESEARCH, vol. 17, no. 6, 1997, pages 355 - 367, XP000886677, Retrieved from the Internet <URL:http://doi.org/10.1089/jir.1997.17.355> |
ROGERS, T. L.; HOLEN, I: "Tumour macrophages as potential targets of bisphosphonates", JOURNAL OF TRANSLATIONAL MEDICINE, vol. 9, no. 1, 2011, pages 177, XP021113601, Retrieved from the Internet <URL:http://doi.org/10.1186/1479-5876-9-177> DOI: doi:10.1186/1479-5876-9-177 |
ROGERS, T. L.; HOLEN, I: "Tumour macrophages as potential targets of bisphosphonates.", JOURNAL OF TRANSLATIONAL MEDICINE, vol. 9, no. 1, 2011, pages 177, XP021113601, Retrieved from the Internet <URL:http://doi.org/10.1186/1479-5876-9-177> DOI: doi:10.1186/1479-5876-9-177 |
SACCANI, A.; SCHIOPPA, T.; PORTA, C.; BISWAS, S. K.; NEBULONI, M.; VAGO, L.; SICA, A.: "p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance", CANCER RESEARCH, vol. 66, no. 23, 2006, pages 11432 - 40, XP055469886, Retrieved from the Internet <URL:http://doi.org/10.158/0008-5472. CAN-06-1867> DOI: doi:10.1158/0008-5472.CAN-06-1867 |
SACCANI, A.; SCHIOPPA, T.; PORTA, C.; BISWAS, S. K.; NEBULONI, M.; VAGO, L.; SICA, A: "p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance", CANCER RESEARCH, vol. 66, no. 23, 2006, pages 11432 - 40, XP055469886, Retrieved from the Internet <URL:http://doi.org/10.1158/0008-5472.CAN-06-1867> DOI: doi:10.1158/0008-5472.CAN-06-1867 |
SANFORD, D. E.; BELT, B. A.; PANNI, R. Z.; MAYER, A.; DESHPANDE, A. D.; CARPENTER, D.; LINEHAN, D. C.: "Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 19, no. 13, 2013, pages 3404 - 15, XP055539775, Retrieved from the Internet <URL:http://doi.org/10.1158/1078-0432.CCR-13-0525> DOI: doi:10.1158/1078-0432.CCR-13-0525 |
SANFORD, D. E.; BELT, B. A.; PANNI, R. Z.; MAYER, A; DESHPANDE, A. D.; CARPENTER, D.; LINEHAN, D. C: "Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis", CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 19, no. 13, 2013, pages 3404 - 15, XP055539775, Retrieved from the Internet <URL:http://doi.org/10.1158/1078-0432.CCR-13-0525> DOI: doi:10.1158/1078-0432.CCR-13-0525 |
SCHMALL, A.; AL-TAMARI, H. M.; HEROLD, S.; KAMPSCHULTE, M.; WEIGERT, A.; WIETELMANN, A.; SAVAI, R.: "Macrophage and Cancer Cell Crosstalk via CCR2 and CX3CR1 is a Fundamental Mechanism Driving Lung Cancer", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE., 2014, Retrieved from the Internet <URL:http://doi.org/10.1164/rccm.201406-11370C> |
SCHMALL, A.; AL-TAMARI, H. M.; HEROLD, S.; KAMPSCHULTE, M.; WEIGERT, A.; WIETELMANN, A.; SAVAI, R.: "Macrophage and Cancer Cell Crosstalk via CCR2 and CX3CR1 is a Fundamental Mechanism Driving Lung Cancer.", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE., 2014, Retrieved from the Internet <URL:http://doi.org/10.1164/rccm.201406-11370C> |
SCHREIBER H: "Cancer Immunology", 2012, LIPPINCOTT-WILLIAMS & WILKINS |
SCHREIBER H: "Tumor-specific immune responses", SEMINLMMUNOL, vol. 20, 2008, pages 265 - 6, XP025646565, Retrieved from the Internet <URL:http://dx.doi.org/10.1016/j.smim.2008.10.001> DOI: doi:10.1016/j.smim.2008.10.001 |
SELIGER B; CABRERA T; GARRIDO F; FERRONE S.: "HLA class I antigen abnormalities and immune escape by malignant cells", SEMIN CANCER BIOL, vol. 12, 2002, pages 3 - 13, XP055547320, Retrieved from the Internet <URL:http://dx.doi.org/10.1006/scbi.2001.0404> DOI: doi:10.1006/scbi.2001.0404 |
SHAW, R. J.: "Glucose metabolism and cancer", CURRENT OPINION IN CELL BIOLOGY, vol. 18, no. 6, 2006, pages 598 - 608, XP024960209, Retrieved from the Internet <URL:http://doi.org/10.1016/j.ceb.2006.10.005> DOI: doi:10.1016/j.ceb.2006.10.005 |
SHU, C. J.; GUO, S.; KIM, Y. J.; SHELLY, S. M.; NIJAGAL, A.; RAY, P.; WITTE, O. N: "Visualization of a primary anti-tumor immune response by positron emission tomography", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 102, no. 48, 2005, pages 17412 - 7, Retrieved from the Internet <URL:http://doi.org/10.1073/pnas.0508698102> |
SHU, C. J.; GUO, S.; KIM, Y. J.; SHELLY, S. M; NIJAGAL, A.; RAY, P.; WITTE, 0. N.: "Visualization of a primary anti-tumor immune response by positron emission tomography", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 102, no. 48, 2005, pages 17412 - 7, Retrieved from the Internet <URL:http://doi.org/10.1073/pnas.0508698102> |
SICA, A.; MANTOVANI, A: "Macrophage plasticity and polarization: in vivo veritas", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 122, no. 3, 2012, pages 787 - 796, XP055111479, Retrieved from the Internet <URL:http:/,Idoi.org/l 0. 1 172/JC159643DS1> DOI: doi:10.1172/JCI59643 |
SICA, A.; MANTOVANI, A: "Macrophage plasticity and polarization: in vivo veritas", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 122, no. 3, 2012, pages 787 - 796, XP055111479, Retrieved from the Internet <URL:http://doi.org/10.1172/JCI59643DS 1> DOI: doi:10.1172/JCI59643 |
SIMONS, J. W.; CARDUCCI, M. A; MIKHAK, B.; LIM, M.; BIEDRZYCKI, B.; BORELLINI, F.; NELSON, W. G.: "Phase l/ll trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer", CLINICAL CANCER RESEARCH, vol. 12, no. 11, 2006, pages 3394 - 401, Retrieved from the Internet <URL:http://doi.org/10.1158/1078-0432.CCR-06-0145> |
SIMPSON, K. D.; TEMPLETON, D. J.; CROSS, J. V.: "Macrophage Migration Inhibitory Factor Promotes Tumor Growth and Metastasis by Inducing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment", THE JOURNAL OF IMMUNOLOGY, 2012, Retrieved from the Internet <URL:http://doi.org/10.4049/jimmunoi.1201161> |
SIMPSON, K. D.; TEMPLETON, D. J.; CROSS, J. V: "Macrophage Migration Inhibitory Factor Promotes Tumor Growth and Metastasis by Inducing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment", THE JOURNAL OF IMMUNOLOGY, 2012, Retrieved from the Internet <URL:http://doi.org/10.4049/jimmunoi.1201161> |
SINHA, P.; CLEMENTS, V. K.; OSTRAND-ROSENBERG, S.: "Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease", JOURNAL OF IMMUNOLOGY, vol. 174, no. 2, 2005, pages 636 - 45, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/15634881> |
SINHA, P.; CLEMENTS, V. K.; OSTRAND-ROSENBERG, S: "Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease", JOURNAL OF IMMUNOLOGY, vol. 174, no. 2, 2005, pages 636 - 45, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov pubmed/15634881> |
SMITH, H. 0.; STEPHENS, N. D.; QUALLS, C. R.; FLIGELMAN, T.; WANG, T.; LIN, C.-Y., .; POLLARD, J. W.: "The clinical significance of inflammatory cytokines in primary cell culture in endometrial carcinoma", MOLECULAR ONCOLOGY, vol. 7, no. 1, 2013, pages 41 - 54, Retrieved from the Internet <URL:http://doi.org/10.1016/j.molonc.2012.07.002> |
SMITH, H. O.; STEPHENS, N. D.; QUALLS, C. R.; FLIGELMAN, T.; WANG, T.; LIN, C.-Y.; POLLARD, J. W.: "The clinical significance of inflammatory cytokines in primary cell culture in endometrial carcinoma", MOLECULAR ONCOLOGY, vol. 7, no. 1, 2013, pages 41 - 54, Retrieved from the Internet <URL:http://doi.org/10.1016/j.molonc.2012.07.002> |
SQUADRITO, M. L.; ETZRODT, M.; DE PALMA, M.; PITTET, M. J.: "MicroRNA-mediated control of macrophages and its implications for cancer", TRENDS IN IMMUNOLOGY, vol. 34, no. 7, 2013, pages 350 - 9, Retrieved from the Internet <URL:http://doi.org/10.1016/j.it.2013.02.003> |
STEIDL, C.; LEE, T.; SHAH, S.: "Tumor-associated macrophages and survival in classic Hodgkin's lymphoma", THE NEW ENGLAND JOURNAL OF MEDICINE, 2010, pages 875 - 885, XP055041466, Retrieved from the Internet <URL:http://www. neim.org/doi/full/10.1056/NEJMoa0905680> DOI: doi:10.1056/NEJMoa0905680 |
STEIDL, C.; LEE, T.; SHAH, S.: "Tumor-associated macrophages and survival in classic Hodgkin's lymphoma", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 362, no. 10, 2010, pages 875 - 885, XP055041466, Retrieved from the Internet <URL:http://www.nejm.org/doi/full/10.1056/NEJMoa0905680> DOI: doi:10.1056/NEJMoa0905680 |
STEIDL, C.; LEE, T.; SHAH, S: "Tumor-associated macrophages and survival in classic Hodgkin's lymphoma", THE NEW ENGLAND JOURNAL OF MEDICINE, 2010, pages 875 - 885, XP055041466, Retrieved from the Internet <URL:http://www.nejm.org/doi/full/10.1056/NEJMoa0905680> DOI: doi:10.1056/NEJMoa0905680 |
STEIDL, C.; LEE, T.; SHAH, S: "Tumor-associated macrophages and survival in classic Hodgkin's lymphoma", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 362, no. 10, 2010, pages 875 - 885, XP055041466, Retrieved from the Internet <URL:http://www.nejm.org/doi/full/10.1056/NEJMoa0905680> DOI: doi:10.1056/NEJMoa0905680 |
STONE, J.D; AGGEN, D.H.; SCHEITINGER, A; SCHREIBER, H; KRANZ, D.M.: "A sensitivity scale for targeting T cells with Chimeric Antigen Receptors (CARs) and Bispecific T -cell engagers (BiTEs", ONCLOMMUNOLOGY, vol. 1, no. 6, 2012, pages 863 - 873, XP055406174, DOI: doi:10.4161/onci.20592 |
URBAN, J. L.; SHEPARD, H. M.; ROTHSTEIN, J. L.; SUGARMAN, B. J.; SCHREIBER, H.: "Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 83, no. 14, 1986, pages 5233 - 7, Retrieved from the Internet <URL:http://www. pubmedcentral.nih. gov/articlerender.fcgi?arlid=323925& tool= pmcentrez&rendertype=abstract> |
URBAN, J. L.; SHEPARD, H. M.; ROTHSTEIN, J. L.; SUGARMAN, B. J.; SCHREIBER, H.: "Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 83, no. 14, 1986, pages 5233 - 7, Retrieved from the Internet <URL:http://www.pubmedcentral. nih.gov/articlerender. fcgi?artid=323925&tool=p mcentrez&rendertype=abstract> |
VAN GINDERACHTER, J. A.; MOVAHEDI, K.; HASSANZADEH GHASSABEH, G.; MEERSCHAUT, S.; BESCHIN, A.; RAES, G.; DE BAETSELIER, P.: "Classical and alternative activation of mononuclear phagocytes: Picking the best of both worlds for tumor promotion", IMMUNOBIOLOGY, vol. 211, no. 6, 2006, pages 487 - 501, XP028020250, Retrieved from the Internet <URL:http:/.Iwww.sciencedirect.com/science/article/pii/SO1712985060008 29> DOI: doi:10.1016/j.imbio.2006.06.002 |
VAN GINDERACHTER, J. A.; MOVAHEDI, K.; HASSANZADEH GHASSABEH, G.; MEERSCHAUT, S.; BESCHIN, A.; RAES, G.; DE BAETSELIER, P.: "Classical and alternative activation of mononuclear phagocytes: Picking the best of both worlds for tumor promotion", IMMUNOBIOLOGY, vol. 211, no. 6, 2006, pages 487 - 501, XP028020250, Retrieved from the Internet <URL:http://www.sciencedirect.com/science/article/pii/S0171298506000829> DOI: doi:10.1016/j.imbio.2006.06.002 |
WANG, Y.-C.; HE, F.; FENG, F.; LIU, X.-W.; DONG, G.-Y.; QIN, H.-Y.; HAN, H.: "Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses", CANCER RESEARCH, vol. 70, no. 12, 2010, pages 4840 - 9, XP009160889, Retrieved from the Internet <URL:http://d i. rg/10.1158/0008-5472.CAN-10-0269> DOI: doi:10.1158/0008-5472.CAN-10-0269 |
WANG, Y.-C.; HE, F.; FENG, F.; LIU, X.-W; DONG, G.-Y.; QIN, H.-Y.; HAN, H.: "Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses", CANCER RESEARCH, vol. 70, no. 12, 2010, pages 4840 - 9, XP009160889, Retrieved from the Internet <URL:http://doi.org/10.1158/0008-5472. CAN-10-0269> DOI: doi:10.1158/0008-5472.CAN-10-0269 |
WEI, Y.; NAZARI-JAHANTIGH, M.; CHAN, L.; ZHU, M.; HEYLL, K.; CORBALAN-CAMPOS, J; SCHOBER, A.: "The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1-and microRNA-155-dependent pathway during atherosclerosis", CIRCULATION, vol. 127, no. 15, 2013, pages 1609 - 19, Retrieved from the Internet <URL:Ihttp://doi.org/10.1161/CIRCULATIONAHA.112.000736> |
WEI, Y.; NAZARI-JAHANTIGH, M.; CHAN, L.; ZHU, M.; HEYLL, K; CORBALAN-CAMPOS, J.; SCHOBER, A: "The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis", CIRCULATION, vol. 127, no. 15, 2013, pages 1609 - 19, Retrieved from the Internet <URL:http://doi.org/10.1161 /CIRCULA TIONAHA112.000736> |
WEST, R. B.; RUBIN, B. P.; MILLER, M. A.; SUBRAMANIAN, S.; KAYGUSUZ, G.; MONTGOMERY, K.; VAN DE RIJN, M.: "A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 103, no. 3, 2006, pages 690 - 5, Retrieved from the Internet <URL:http://doi.org/10.1073/pnas.0507321103> |
WOLF, A.; AGNIHOTRI, S.; MICALLEF, J.; MUKHERJEE, J.; SABHA, N.; CAIRNS, R.; GUHA, A.: "Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 208, no. 2, 2011, pages 313 - 26, XP055521122, Retrieved from the Internet <URL:http://doi.org/10.1084/jem.20101470> DOI: doi:10.1084/jem.20101470 |
WOLF, A.; AGNIHOTRI, S.; MICALLEF, J.; MUKHERJEE, J.; SABHA, N.; CAIRNS, R.; GUHA, A.: "Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 208, no. 2, 2011, pages 313 - 26, XP055521122, Retrieved from the Internet <URL:ttp://doi.org/10.1084/jem.20101470> DOI: doi:10.1084/jem.20101470 |
WONG, S.-C.; PUAUX, A.-L.; CHITTEZHATH, M.; SHALOVA, I.; KAJIJI, T. S.; WANG, X.; BISWAS, S. K: "Macrophage polarization to a unique phenotype driven by B cells", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 40, no. 8, 2010, pages 2296 - 307, Retrieved from the Internet <URL:http://doi.org/10.1002/eji.200940288> |
WONG, S.-C.; PUAUX, A.-L; CHITTEZHATH, M.; SHALOVA, I.; KAJIJI, T. S.; WANG, X.; BISWAS, S. K.: "Macrophage polarization to a unique phenotype driven by B cells", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 40, no. 8, 2010, pages 2296 - 307, Retrieved from the Internet <URL:http://doi.org/10.1002/eji.200940288> |
YU Z; THEORET MR; TOULOUKIAN CE; SURMAN DR; GARMAN SC; FEIGENBAUM L ET AL.: "Poor immunogenicityof a self/tumor antigen derives from peptide-MHCI instability and is independent of tolerance", J CLIN INVEST, vol. 114, 2004, pages 551 - 9 |
ZEISBERGER, S. M.; ODERMATT, B.; MARTY, C.; ZEHNDER-FJALLMAN, A H. M.; BALLMER-HOFER, K.; SCHWENDENER, R. A.: "Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach", BRITISH JOURNAL OF CANCER, vol. 95, no. 3, 2006, pages 272 - 81, XP003020894, Retrieved from the Internet <URL:http://doi.org/10.1038/si.bic.6603240> DOI: doi:10.1038/sj.bjc.6603240 |
ZEISBERGER, S. M.; ODERMATT, B.; MARTY, C.; ZEHNDER-FJALLMAN, A H. M.; BALLMER-HOFER, K.; SCHWENDENER, R. A: "Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach", BRITISH JOURNAL OF CANCER, vol. 95, no. 3, 2006, pages 272 - 81, XP003020894, Retrieved from the Internet <URL:http://doi.org/10.1038/sj.bjc.6603240> DOI: doi:10.1038/sj.bjc.6603240 |
ZHANG, F.; LU, W.; DONG, Z: "Tumor-infiltrating macrophages are involved in suppressing growth and metastasis of human prostate cancer cells by INF-? gene therapy in nude mice", CLINICAL CANCER RESEARCH, 2002, pages 2942 - 2951, Retrieved from the Internet <URL:http://clincancerres. aacrmournals. org/content/8/9/2942. short> |
ZHANG, F.; LU, W.; DONG, Z: "Tumor-infiltrating macrophages are involved in suppressing growth and metastasis of human prostate cancer cells by INF-? gene therapy in nude mice", CLINICAL CANCER RESEARCH, 2002, pages 2942 - 2951, Retrieved from the Internet <URL:http://clincancerres.aacrjournals.org/content/8/9/2942.short> |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11918604B2 (en) | 2015-02-19 | 2024-03-05 | Myeloid Therapeutics, Inc. | Chimeric antigen receptor dendritic cell (CAR-DC) for treatment of cancer |
US11918605B1 (en) | 2015-02-19 | 2024-03-05 | Myeloid Therapeutics, Inc. | Chimeric antigen receptor dendritic cell (CAR-DC) for treatment of cancer |
US11517589B2 (en) | 2015-02-19 | 2022-12-06 | Myeloid Therapeutics, Inc. | Chimeric antigen receptor dendritic cell (CAR-DC) for treatment of cancer |
US11052138B2 (en) | 2015-05-20 | 2021-07-06 | Thunder Biotech Inc. | Use of car and bite technology coupled with an SCFV from an antibody against human thymidine kinase 1 to specifically target tumors |
US11352439B2 (en) | 2015-08-13 | 2022-06-07 | Kim Leslie O'Neill | Macrophage CAR (MOTO-CAR) in immunotherapy |
US11655282B2 (en) | 2016-09-27 | 2023-05-23 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
JP2020520252A (en) * | 2017-05-17 | 2020-07-09 | サンダー・バイオテック・インコーポレイテッド | Transgenic macrophages, chimeric antigen receptors, and related methods |
KR20200020708A (en) * | 2017-05-17 | 2020-02-26 | 썬더 바이오테크 인크. | Transformed Macrophages, Chimeric Antigen Receptors, and Related Methods |
US10415017B2 (en) | 2017-05-17 | 2019-09-17 | Thunder Biotech, Inc. | Transgenic macrophages, chimeric antigen receptors, and associated methods |
WO2018212770A1 (en) * | 2017-05-17 | 2018-11-22 | Thunder Biotech Inc. | Transgenic macrophages, chimeric antigen receptors, and associated methods |
JP7164598B2 (en) | 2017-05-17 | 2022-11-01 | サンダー・バイオテック・インコーポレイテッド | Transgenic macrophages, chimeric antigen receptors, and related methods |
CN110662553A (en) * | 2017-05-17 | 2020-01-07 | 迅雷生物科技有限公司 | Transgenic macrophages, chimeric antigen receptors and related methods |
US10889803B2 (en) | 2017-05-17 | 2021-01-12 | Thunder Biotech, Inc | Transgenic macrophages, chimeric antigen receptors, and associated methods |
KR102508182B1 (en) * | 2017-05-17 | 2023-03-09 | 썬더 바이오테크 인크. | Transformed macrophages, chimeric antigen receptors, and related methods |
US11708423B2 (en) | 2017-09-26 | 2023-07-25 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules and methods of use |
WO2020048341A1 (en) * | 2018-09-04 | 2020-03-12 | 华瑞同康生物技术(深圳)有限公司 | Mammalian cell recombinant anti-human tk1 monoclonal antibody of chicken origin, single-chain antibody, preparation method therefor and application thereof |
WO2020176605A1 (en) * | 2019-02-26 | 2020-09-03 | The University Of Vermont And State Agricultural College | Antibodies to neoantigens and uses thereof |
EP3962497A4 (en) * | 2019-04-30 | 2023-01-18 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
US11672874B2 (en) | 2019-09-03 | 2023-06-13 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
GB2608279A (en) * | 2019-12-11 | 2022-12-28 | Myeloid Therapeutics Inc | Therapeutic cell compositions and methods for manufacture and uses thereof |
WO2021119538A1 (en) * | 2019-12-11 | 2021-06-17 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods for manufacture and uses thereof |
US11628218B2 (en) | 2020-11-04 | 2023-04-18 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
WO2022248602A1 (en) * | 2021-05-25 | 2022-12-01 | Institut Curie | Myeloid cells overexpressing bcl2 |
Also Published As
Publication number | Publication date |
---|---|
KR20180054600A (en) | 2018-05-24 |
CN108137704A (en) | 2018-06-08 |
EP3334764A2 (en) | 2018-06-20 |
WO2017025944A3 (en) | 2017-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11352439B2 (en) | Macrophage CAR (MOTO-CAR) in immunotherapy | |
WO2017025944A2 (en) | Macrophage car (moto-car) in imunotherapy | |
US10889803B2 (en) | Transgenic macrophages, chimeric antigen receptors, and associated methods | |
US11913075B2 (en) | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer | |
ES2897579T3 (en) | Methods and compositions for reducing immunosuppression by tumor cells | |
Ren et al. | Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity | |
Keremu et al. | Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines | |
JP7164598B2 (en) | Transgenic macrophages, chimeric antigen receptors, and related methods | |
Wang et al. | Targeted immunotherapies in gastrointestinal cancer: From molecular mechanisms to implications | |
WO2017075465A1 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 | |
Fang et al. | The potential regulatory roles of circular RNAs in tumor immunology and immunotherapy | |
US20210052643A1 (en) | Modified macrophages and macrophage precursors and associated methods | |
JP2022546282A (en) | Combination therapy with GOLD-regulated transgenes | |
US20220372170A1 (en) | Macrophage CAR (MOTO-CAR) In Immunotherapy | |
AU2016305353B2 (en) | Macrophage chimeric antigen receptor (MOTO-CAR) in imunotherapy | |
WO2022125392A1 (en) | Compositions and methods for activating t-cells | |
KR20220165255A (en) | Composition and method for enhancing activation and cytolytic activity of CD8+ T cells through destruction of SAGA (SPT-ADA-GCN5-acetyltransferase) complex | |
US20210069245A1 (en) | Mirna modulation of t cell signaling and uses thereof | |
Rotolo et al. | Unedited allogeneic iNKT cells show extended persistence in MHC-mismatched canine recipients | |
Xu et al. | frontiers Frontiers in Oncology REVIEW published: 04 July 2022 | |
WO2023056193A2 (en) | Il-18 variants and uses thereof | |
WO2023049768A1 (en) | Fibp knockout in t cells amplifies antitumor activity by limiting cholesterol metabolism, suggesting a potentiator of adoptive cell therapy | |
CN116234908A (en) | Morpholino to promote FOXP3S |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16801306 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2998406 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20187007097 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201890489 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11201802046Y Country of ref document: SG Ref document number: 2016801306 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016305353 Country of ref document: AU Date of ref document: 20161013 Kind code of ref document: A |